- Home
- Software Solutions
- Resources
- Corporate
News feeds from around the industry (Updated Hourly) - Updated on February 23, 2012
b3c newswire
>Sol-Gel Signs $ 27 M Deal for Dermatology Drug DeliveryB3C newswire (http://www.b3cnewswire.com/home.html) / Sol-Gel Technologies Ltd. (http://www.sol-gel.com/) announced today that it has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company for the development and commercialization in the U.S. and Canada of a major dermatologic drug. Under the terms of the new agreement, Sol-Gel will receive $27 million, comprised of an initial non-refundable payment as well as additional license fees and developm...
>Critical Pharmaceuticals and The University of Nottingham to Develop Nano-Enabled Nasal Spray ...B3C newswire (http://www.b3cnewswire.com/home.html) / Critical Pharmaceuticals (http://www.criticalpharmaceuticals.com/), an emerging biotechnology company, and The University of Nottingham today announce a £545,000 collaboration to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis. Osteoporosis affects an estimated 75 million people in Europe, US and Japan with more than 180,000 patients suffer fragility fractures in the UK alone
>TGA Registration for Cellmid's Évolis(TM) Hair ProductsB3C newswire (http://www.b3cnewswire.com/home.html) - Cellmid Limited (http://www.cellmid.com.au/) (ASX: CDY) advises that it has received TGA registration for its ?olis™ hair growth product range as “listed medicine”. The registration certificates for the ?olis™ for Men and ?olis™ for Women products include the important claims of “promotes hair growth”, “helps prevent hair loss and thinning” and “restores the natural hair growth cy...
>AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human ...B3C newswire (http://www.b3cnewswire.com/home.html) - AiCuris GmbH &Co KG (http://www.aicuris.com/), a clinical stage biopharmaceutical company developing drugs against severe infectious diseases, announces positive results from its placebo-controlled and dose-ranging trial with Letermovir (AIC246). In addition to excellent efficacy Letermovir demonstrates superior tolerability and safety and thus defines a novel standard for the control of HCMV in transplant patients. 133 HCMV-seropositive ...
>Vectron Biosolutions Obtains Strong Results for Biosimilar ProductionB3C newswire (http://www.b3cnewswire.com/home.html) - Vectron Biosolutions (http://www.vectronbiosolutions.com/) announced today that they have obtained strong results for manufacture of selected biosimilar proteins using their proprietary E. coli expression technology. The study was done side-by-side with other expression technologies and Vectron’s technology gave higher soluble and/or insoluble yields for seven out of 10 tested biosimilar proteins. The increase in yield was 2 to 25 ti...
>Sol-Gel Signs $ 27 M Deal for Dermatology Drug DeliveryB3C newswire (http://www.b3cnewswire.com/home.html) / Sol-Gel Technologies Ltd. (http://www.sol-gel.com/) announced today that it has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company for the development and commercialization in the U.S. and Canada of a major dermatologic drug. Under the terms of the new agreement, Sol-Gel will receive $27 million, comprised of an initial non-refundable payment as well as additional license fees and developm...
>Critical Pharmaceuticals and The University of Nottingham to Develop Nano-Enabled Nasal Spray ...B3C newswire (http://www.b3cnewswire.com/home.html) / Critical Pharmaceuticals (http://www.criticalpharmaceuticals.com/), an emerging biotechnology company, and The University of Nottingham today announce a £545,000 collaboration to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis. Osteoporosis affects an estimated 75 million people in Europe, US and Japan with more than 180,000 patients suffer fragility fractures in the UK alone
>TGA Registration for Cellmid's Évolis(TM) Hair ProductsB3C newswire (http://www.b3cnewswire.com/home.html) - Cellmid Limited (http://www.cellmid.com.au/) (ASX: CDY) advises that it has received TGA registration for its ?olis™ hair growth product range as “listed medicine”. The registration certificates for the ?olis™ for Men and ?olis™ for Women products include the important claims of “promotes hair growth”, “helps prevent hair loss and thinning” and “restores the natural hair growth cy...
>AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human ...B3C newswire (http://www.b3cnewswire.com/home.html) - AiCuris GmbH &Co KG (http://www.aicuris.com/), a clinical stage biopharmaceutical company developing drugs against severe infectious diseases, announces positive results from its placebo-controlled and dose-ranging trial with Letermovir (AIC246). In addition to excellent efficacy Letermovir demonstrates superior tolerability and safety and thus defines a novel standard for the control of HCMV in transplant patients. 133 HCMV-seropositive ...
>Vectron Biosolutions Obtains Strong Results for Biosimilar ProductionB3C newswire (http://www.b3cnewswire.com/home.html) - Vectron Biosolutions (http://www.vectronbiosolutions.com/) announced today that they have obtained strong results for manufacture of selected biosimilar proteins using their proprietary E. coli expression technology. The study was done side-by-side with other expression technologies and Vectron’s technology gave higher soluble and/or insoluble yields for seven out of 10 tested biosimilar proteins. The increase in yield was 2 to 25 ti...
BioSpace
>GlaxoSmithKline Trying for Culture Shift ... and More Profit Coming out of 2011, GlaxoSmithKline hopes that it turned a corner, with leaders saying they hope several years of changes will result in higher and more consistent profits, but also a bit more civic good. "We want to have the right people, acting the right way with the right set of values," North American pharmaceutical president Deirdre Connelly said from the company's Center City Philadelphia office...
>Actelion Ltd. CEO Says 120 Patients Died in Lung Drug Study Actelion Ltd. (ATLN), the Swiss drugmaker, said 120 people died in a clinical trial of more than 700 patients involving its experimental medicine macitentan. The drug is very unlikely to show a statistically significant benefit in extending the lives of patients with pulmonary arterial hypertension, though the company is confident the trial will show patients are helped by the product, Chief Executive...
>Celladon Corporation Raises $43 Million to Advance MYDICAR?? for the Treatment of Heart Failure LA JOLLA, Calif., Feb. 15, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has completed a $43 million equity financing to advance its lead investigational product candidate MYDICAR for the treatment...
>Cold Baths May Help Ease Muscle Soreness After Workouts, Study Taking a cold-water or ice bath may reduce exercise-related muscle soreness but it's not clear whether it can cause harmful side effects, a new evidence review indicates. The use of cold or ice baths is increasingly popular among elite and amateur athletes as a way to reduce muscle inflammation that can lead to stiffness, swelling and soreness a day or more after a workout.
>Nestle SA Invests ???50 Million in 5-year Probiotic Licensing Deal With STOCKHOLM, Feb. 15, 2012 /PRNewswire/ -- Since 2008, BioGaia and Nestle have collaborated in the field of infant nutrition products. The parties have now signed agreements to extend this collaboration. These agreements are of significant strategic value for BioGaia since they not only involve an extended close collaboration with Nestle but also generate a greater financial freedom for BioGaia to further...
>GlaxoSmithKline Trying for Culture Shift ... and More Profit Coming out of 2011, GlaxoSmithKline hopes that it turned a corner, with leaders saying they hope several years of changes will result in higher and more consistent profits, but also a bit more civic good. "We want to have the right people, acting the right way with the right set of values," North American pharmaceutical president Deirdre Connelly said from the company's Center City Philadelphia office...
>Actelion Ltd. CEO Says 120 Patients Died in Lung Drug Study Actelion Ltd. (ATLN), the Swiss drugmaker, said 120 people died in a clinical trial of more than 700 patients involving its experimental medicine macitentan. The drug is very unlikely to show a statistically significant benefit in extending the lives of patients with pulmonary arterial hypertension, though the company is confident the trial will show patients are helped by the product, Chief Executive...
>Celladon Corporation Raises $43 Million to Advance MYDICAR?? for the Treatment of Heart Failure LA JOLLA, Calif., Feb. 15, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has completed a $43 million equity financing to advance its lead investigational product candidate MYDICAR for the treatment...
>Cold Baths May Help Ease Muscle Soreness After Workouts, Study Taking a cold-water or ice bath may reduce exercise-related muscle soreness but it's not clear whether it can cause harmful side effects, a new evidence review indicates. The use of cold or ice baths is increasingly popular among elite and amateur athletes as a way to reduce muscle inflammation that can lead to stiffness, swelling and soreness a day or more after a workout.
>Nestle SA Invests ???50 Million in 5-year Probiotic Licensing Deal With STOCKHOLM, Feb. 15, 2012 /PRNewswire/ -- Since 2008, BioGaia and Nestle have collaborated in the field of infant nutrition products. The parties have now signed agreements to extend this collaboration. These agreements are of significant strategic value for BioGaia since they not only involve an extended close collaboration with Nestle but also generate a greater financial freedom for BioGaia to further...
BioSpace - Breaking News
>Hutchison Medipharma Starts Phase I Trial of Fourth Cancer Molecule February 22, 2012 -- Hutchison MediPharma, the drug discovery company majority owned by Chi-Med, began a first-in-human Phase I clinical trial of a cancer drug, volitinib (HMPL-504), in Australia. Volitinib, the fourth cancer drug candidate that the company has put into clinical trials, is a novel inhibitor of the c-Met receptor tyrosine kinase. In December 2011, Hutchison MediPharma entered a co...
>Kennedy Krieger Institute Release: New Study Shows Minority Toddlers with Autism are More Delayed than Affected Caucasian Peers Increased Awareness Among Clinicians and Parents Could Lead to Earlier Diagnosis and Intervention for Minority Children with ASDBALTIMORE, Feb. 21, 2012 /PRNewswire-USNewswire/ -- The first prospective study of ethnic differences in the symptoms of autism in toddlers shows...
>UCB, Inc. Announces Start of C-EARLY(TM) Study BRUSSELS, Feb. 22, 2012 /PRNewswire/ -- UCB today announced the start of C-EARLY a phase III study that will evaluate the efficacy and safety of Cimzia (certolizumab pegol) in combination with methotrexate (MTX) for inducing and sustaining clinical response in adults with early, progressive, active, moderate...
>Johnson & Johnson CEO Out, Successor Named NEW BRUNSWICK, N.J., Feb. 21, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced that its Board of Directors has named Alex Gorsky Chief Executive Officer (CEO) of Johnson & Johnson effective April 26, 2012, the date of the Company's Annual Meeting of Shareholders. Mr. Gorsky was...
>Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) Receives Notice of Allowance for U.S. Patent Related to Its Lipid Based Nucleic Acid Drug Delivery Platform BOTHELL, WA--(Marketwire - February 22, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 10/505,107 with claims that...
>Hutchison Medipharma Starts Phase I Trial of Fourth Cancer Molecule February 22, 2012 -- Hutchison MediPharma, the drug discovery company majority owned by Chi-Med, began a first-in-human Phase I clinical trial of a cancer drug, volitinib (HMPL-504), in Australia. Volitinib, the fourth cancer drug candidate that the company has put into clinical trials, is a novel inhibitor of the c-Met receptor tyrosine kinase. In December 2011, Hutchison MediPharma entered a co...
>Kennedy Krieger Institute Release: New Study Shows Minority Toddlers with Autism are More Delayed than Affected Caucasian Peers Increased Awareness Among Clinicians and Parents Could Lead to Earlier Diagnosis and Intervention for Minority Children with ASDBALTIMORE, Feb. 21, 2012 /PRNewswire-USNewswire/ -- The first prospective study of ethnic differences in the symptoms of autism in toddlers shows...
>UCB, Inc. Announces Start of C-EARLY(TM) Study BRUSSELS, Feb. 22, 2012 /PRNewswire/ -- UCB today announced the start of C-EARLY a phase III study that will evaluate the efficacy and safety of Cimzia (certolizumab pegol) in combination with methotrexate (MTX) for inducing and sustaining clinical response in adults with early, progressive, active, moderate...
>Johnson & Johnson CEO Out, Successor Named NEW BRUNSWICK, N.J., Feb. 21, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced that its Board of Directors has named Alex Gorsky Chief Executive Officer (CEO) of Johnson & Johnson effective April 26, 2012, the date of the Company's Annual Meeting of Shareholders. Mr. Gorsky was...
>Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) Receives Notice of Allowance for U.S. Patent Related to Its Lipid Based Nucleic Acid Drug Delivery Platform BOTHELL, WA--(Marketwire - February 22, 2012) - Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 10/505,107 with claims that...
Biotech News - Business Wire
>La conférence Partnering For Global Impact® 2012 se tiendra en juillet à Lugano, en SuisseZURICH & LUGANO, Suisse--(BUSINESS WIRE)--Le Groupe EBD, principale société de partenariat de l'industrie des sciences de la vie, a annoncé aujourd'hui que la conférence inaugurale Partnering for Global Impact®se tiendra les 9 et 10 juillet 2012 au Centre de conventions de Lugano, en Suisse. La conférence Partnering for Global Impact utilisera le système partneringONE® du Groupe EBD pour fournir une plate-forme de collaboration efficace entre les investisseurs du secteur de l' "impact investi...
>Allergan Receives Positive Opinions for First-of-Its-Kind, Fully in vitro, Cell-Based Assay for BOTOX® and VISTABEL®MARLOW, England--(BUSINESS WIRE)--Allergan is pleased to announce the company has received two positive opinions regarding its fully in vitro, cell-based assay for use in the stability and potency testing of BOTOX® and VISTABEL® (Allergan?s botulinum toxin type A products). Upon approval, the new assay will be implemented as quickly as possible for the release of product for sale in the relevant countries. Allergan estimates that use of the new assay will reduce the use of animal-based assay ...
>Riassunto: Il convegno Partnering For Global Impact® 2012 si terrà a luglio in Svizzera, nella città di LuganoZURIGO E LUGANO, Svizzera--(BUSINESS WIRE)--EBD Group, società leader nei servizi di partenariato per l'industria biologica mondiale, ha annunciato oggi che il convegno inaugurale Partnering for Global Impact® si terrà il 9-10 luglio presso il Palazzo dei Congressi di Lugano. Utilizzando il sistema partneringONE® elaborato da EDB Group, Partnering for Global Impact fornirà un'efficace piattaforma per facilitare la collaborazione tra investitori responsabili, filantropi, imprenditori sociali e...
>Michael P. Simpson Joins Small Bone Innovations as President and CEONEW YORK--(BUSINESS WIRE)--Michael P. Simpson is the new President & CEO of Small Bone Innovations, Inc., the privately-owned orthopedic device company. Replaces Anthony G. Viscogliosi, SBI's founder, now Executive CM.
>Partnering For Global Impact® 2012 findet im Juli in Lugano, in der Schweiz stattZÜRICH & LUGANO, Schweiz--(BUSINESS WIRE)--EBD Group, die führende Partnering-Gesellschaft für die Biotechnologiebranche, verkündete heute, dass die Eröffnungskonferenz Partnering for Global Impact® vom 9.-10. Juli 2012 in Lugano in der Schweiz im Lugano Convention Centre stattfinden wird. Partnering for Global Impact wird das Kontaktsystem partneringONE® der EBD Group nutzen, um eine effektive Plattform für die Zusammenarbeit zwischen Impact Investoren, Philanthropen, Sozialunternehmern und ...
>La conférence Partnering For Global Impact® 2012 se tiendra en juillet à Lugano, en SuisseZURICH & LUGANO, Suisse--(BUSINESS WIRE)--Le Groupe EBD, principale société de partenariat de l'industrie des sciences de la vie, a annoncé aujourd'hui que la conférence inaugurale Partnering for Global Impact®se tiendra les 9 et 10 juillet 2012 au Centre de conventions de Lugano, en Suisse. La conférence Partnering for Global Impact utilisera le système partneringONE® du Groupe EBD pour fournir une plate-forme de collaboration efficace entre les investisseurs du secteur de l' "impact investi...
>Allergan Receives Positive Opinions for First-of-Its-Kind, Fully in vitro, Cell-Based Assay for BOTOX® and VISTABEL®MARLOW, England--(BUSINESS WIRE)--Allergan is pleased to announce the company has received two positive opinions regarding its fully in vitro, cell-based assay for use in the stability and potency testing of BOTOX® and VISTABEL® (Allergan?s botulinum toxin type A products). Upon approval, the new assay will be implemented as quickly as possible for the release of product for sale in the relevant countries. Allergan estimates that use of the new assay will reduce the use of animal-based assay ...
>Riassunto: Il convegno Partnering For Global Impact® 2012 si terrà a luglio in Svizzera, nella città di LuganoZURIGO E LUGANO, Svizzera--(BUSINESS WIRE)--EBD Group, società leader nei servizi di partenariato per l'industria biologica mondiale, ha annunciato oggi che il convegno inaugurale Partnering for Global Impact® si terrà il 9-10 luglio presso il Palazzo dei Congressi di Lugano. Utilizzando il sistema partneringONE® elaborato da EDB Group, Partnering for Global Impact fornirà un'efficace piattaforma per facilitare la collaborazione tra investitori responsabili, filantropi, imprenditori sociali e...
>Michael P. Simpson Joins Small Bone Innovations as President and CEONEW YORK--(BUSINESS WIRE)--Michael P. Simpson is the new President & CEO of Small Bone Innovations, Inc., the privately-owned orthopedic device company. Replaces Anthony G. Viscogliosi, SBI's founder, now Executive CM.
>Partnering For Global Impact® 2012 findet im Juli in Lugano, in der Schweiz stattZÜRICH & LUGANO, Schweiz--(BUSINESS WIRE)--EBD Group, die führende Partnering-Gesellschaft für die Biotechnologiebranche, verkündete heute, dass die Eröffnungskonferenz Partnering for Global Impact® vom 9.-10. Juli 2012 in Lugano in der Schweiz im Lugano Convention Centre stattfinden wird. Partnering for Global Impact wird das Kontaktsystem partneringONE® der EBD Group nutzen, um eine effektive Plattform für die Zusammenarbeit zwischen Impact Investoren, Philanthropen, Sozialunternehmern und ...
Biotech News - PR Newswire
>Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEOAMARILLO, Texas, Feb. 22, 2012 /PRNewswire/ -- Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that Dr. Stephen T. Chen has been appointed as Chairman of the Board and Chief Executive Officer. Dr. Joseph Cummins will remain as President and become Chief...
>ERT to Present at the Citi 2012 Global Health Care Conference February 29, 2012PHILADELPHIA, Feb. 22, 2012 /PRNewswire/ -- ERT (Nasdaq: ERT), announced today that Dr. Jeffrey S. Litwin, the Company's President and CEO is scheduled to present at the Citi 2012 Global Health Care Conference at 9:30AM EST on Feb. 29, 2012 in New York. Interested parties may access...
>Questcor Reports Fourth Quarter and Full Year 2011 Financial ResultsANAHEIM, Calif., Feb. 22, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2011. Net sales for the fourth quarter were $75.5 million, reflecting continued physician acceptance...
>Express Scripts Reports Fourth Quarter ResultsST. LOUIS, Feb. 22, 2012 /PRNewswire/ -- Express Scripts, Inc. (Nasdaq: ESRX) announced 2011 fourth quarter and full year net income from continuing operations of $290.4 million and $1,275.8 million, or $0.59 and $2.53 per diluted share, respectively. Adjusted earnings per share, as...
>Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare ConferenceSAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Citi 2012 Global Healthcare Conference in New York on Wednesday, February 29, 2012 at 11:00 a.m. ET / 8:00 a.m. PT. Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics,...
>Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEOAMARILLO, Texas, Feb. 22, 2012 /PRNewswire/ -- Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that Dr. Stephen T. Chen has been appointed as Chairman of the Board and Chief Executive Officer. Dr. Joseph Cummins will remain as President and become Chief...
>ERT to Present at the Citi 2012 Global Health Care Conference February 29, 2012PHILADELPHIA, Feb. 22, 2012 /PRNewswire/ -- ERT (Nasdaq: ERT), announced today that Dr. Jeffrey S. Litwin, the Company's President and CEO is scheduled to present at the Citi 2012 Global Health Care Conference at 9:30AM EST on Feb. 29, 2012 in New York. Interested parties may access...
>Questcor Reports Fourth Quarter and Full Year 2011 Financial ResultsANAHEIM, Calif., Feb. 22, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2011. Net sales for the fourth quarter were $75.5 million, reflecting continued physician acceptance...
>Express Scripts Reports Fourth Quarter ResultsST. LOUIS, Feb. 22, 2012 /PRNewswire/ -- Express Scripts, Inc. (Nasdaq: ESRX) announced 2011 fourth quarter and full year net income from continuing operations of $290.4 million and $1,275.8 million, or $0.59 and $2.53 per diluted share, respectively. Adjusted earnings per share, as...
>Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare ConferenceSAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Citi 2012 Global Healthcare Conference in New York on Wednesday, February 29, 2012 at 11:00 a.m. ET / 8:00 a.m. PT. Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics,...
Biotechnology - Moreover
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)(Financial News Network On) Here are 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were underperforming. This is what we found:
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)(Financial News Network On) We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at yesterday's price
>NIH Translational Center Should ?Raise All Boats,? BIO SaysExtract not available.
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly updateImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the threemonth period ended December
>Biotechnology to be 21st-century industry: Life Tech CEOClick on the link to read the full article at Xinhua
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)(Financial News Network On) Here are 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were underperforming. This is what we found:
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)(Financial News Network On) We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at yesterday's price
>NIH Translational Center Should ?Raise All Boats,? BIO SaysExtract not available.
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly updateImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the threemonth period ended December
>Biotechnology to be 21st-century industry: Life Tech CEOClick on the link to read the full article at Xinhua
Burrill Report
>The March 2012 Issue of The Burrill Report
>Proposed FDA Budget Leans on Industry Federal funding for the U.S. Food and Drug Administration will remain roughly flat in fiscal 2013, with user fee programs funding about 45 percent of the agency’s overall budget.
>Gilead Drops on Poor Clinical Trials Results of Pharmasset DrugJust months after paying $11 billion to acquire Pharmasset and gain rights to its key compound (now called GS-7977) for the treatment of Hepatitis C, Gilead has reported that the compound failed to suppress the virus in mid-stage trials.
>Rusnano Invests in Novel DiagnosticsRusnano intends to bring the next generation of diagnostics to Russia. The government-backed investment firm has signed a letter of intent for an investment in the French diagnostics developer Magnisense to enable it to establish a manufacturing facility in Russia for the Russian market and for export.
>Despite Cuts, Big Pharma Says It's Still OverstaffedIn 2011, Big Pharma companies made deep cuts to their salesforces as they contended with a loss of patent protection on some of the top-selling drugs in the industry.
>The March 2012 Issue of The Burrill Report
>Proposed FDA Budget Leans on Industry Federal funding for the U.S. Food and Drug Administration will remain roughly flat in fiscal 2013, with user fee programs funding about 45 percent of the agency’s overall budget.
>Gilead Drops on Poor Clinical Trials Results of Pharmasset DrugJust months after paying $11 billion to acquire Pharmasset and gain rights to its key compound (now called GS-7977) for the treatment of Hepatitis C, Gilead has reported that the compound failed to suppress the virus in mid-stage trials.
>Rusnano Invests in Novel DiagnosticsRusnano intends to bring the next generation of diagnostics to Russia. The government-backed investment firm has signed a letter of intent for an investment in the French diagnostics developer Magnisense to enable it to establish a manufacturing facility in Russia for the Russian market and for export.
>Despite Cuts, Big Pharma Says It's Still OverstaffedIn 2011, Big Pharma companies made deep cuts to their salesforces as they contended with a loss of patent protection on some of the top-selling drugs in the industry.
CenterWatch - Clinical Trials
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trendCould last Wednesday?s $20 billion Sanofi-aventis acquisition of Genzyme signal the beginning of an industry trend in which big pharmaceutical companies stop buying each other and start buying robust biotechnology firms? Some industry observers think so. ...
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertisingWhen an investigative site does not have enough potential subjects within its own patient base for a particular trial it has taken on, one of the tasks it faces is placing ads in local media outlets. Traditionally, this has involved producing with the ad or hiring talent to do so, obtaining IRB approval for the messages in the ad, determining in which newspaper, TV and/or radio station the ad should run and at what time of day, and then negotiating with those media outlets?often with less tha...
>Technology companies adapt interactive video concepts for clinical trial informed consentInteractive videos, complete with soothing voices, explain hospital surgeries step-by-step, along with the risks and benefits, to enable patients to make informed decisions. Now, producers of these videos are adapting them for the clinical trials space, which for decades has relied on paper documents that often fail to adequately inform prospective volunteers. A number of small companies that have developed interactive technology for hospitals and ophthalmology and cardiology physician practi...
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phasesConsolidation in the investigative-site space continues. CRI Worldwide of Mount Laurel, N.J., has acquired Lifetree Clinical Research of Salt Lake City, Utah, in a cash deal. Both are large, multi-phase sites with early-phase units. With the purchase, CRI now boasts 120 beds. The acquisition, said CRI senior executive Lawrence Brownstein, was spurred by the company?s desire to round out offerings across all phases. CRI, in business 11 years, had grown tired of having to turn away sponsors, he...
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failureA billion-dollar U.S. government drug development center, which will focus on moving potential new discoveries out of the lab and into early-phase trials, could help biopharmaceutical companies improve their success rate in developing new treatments by reducing the risk of failure in early-stage research. According to the Pharmaceutical Research Manufacturers of America (PhRMA), the biopharmaceutical research sector invested an estimated $65.3 billion to discover and develop new medicines in ...
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trendCould last Wednesday?s $20 billion Sanofi-aventis acquisition of Genzyme signal the beginning of an industry trend in which big pharmaceutical companies stop buying each other and start buying robust biotechnology firms? Some industry observers think so. ...
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertisingWhen an investigative site does not have enough potential subjects within its own patient base for a particular trial it has taken on, one of the tasks it faces is placing ads in local media outlets. Traditionally, this has involved producing with the ad or hiring talent to do so, obtaining IRB approval for the messages in the ad, determining in which newspaper, TV and/or radio station the ad should run and at what time of day, and then negotiating with those media outlets?often with less tha...
>Technology companies adapt interactive video concepts for clinical trial informed consentInteractive videos, complete with soothing voices, explain hospital surgeries step-by-step, along with the risks and benefits, to enable patients to make informed decisions. Now, producers of these videos are adapting them for the clinical trials space, which for decades has relied on paper documents that often fail to adequately inform prospective volunteers. A number of small companies that have developed interactive technology for hospitals and ophthalmology and cardiology physician practi...
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phasesConsolidation in the investigative-site space continues. CRI Worldwide of Mount Laurel, N.J., has acquired Lifetree Clinical Research of Salt Lake City, Utah, in a cash deal. Both are large, multi-phase sites with early-phase units. With the purchase, CRI now boasts 120 beds. The acquisition, said CRI senior executive Lawrence Brownstein, was spurred by the company?s desire to round out offerings across all phases. CRI, in business 11 years, had grown tired of having to turn away sponsors, he...
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failureA billion-dollar U.S. government drug development center, which will focus on moving potential new discoveries out of the lab and into early-phase trials, could help biopharmaceutical companies improve their success rate in developing new treatments by reducing the risk of failure in early-stage research. According to the Pharmaceutical Research Manufacturers of America (PhRMA), the biopharmaceutical research sector invested an estimated $65.3 billion to discover and develop new medicines in ...
Clinical Trials - Business Wire
>Nearing Goal of 100 Young Investigators, the Prostate Cancer Foundation Expands Global Research EnterpriseSANTA MONICA, Calif.--(BUSINESS WIRE)--Committed to funding the most innovative minds in the field of prostate cancer research, the Prostate Cancer Foundation (PCF) expanded its global knowledge exchange in 2012 and will be expanding its research efforts in new countries later this year. A total of 15 competitive research grants have been awarded to-date in 2012, bringing the total of young investigators awarded to 89. Young Investigator awards are designed to promote long-term careers in the...
>NinePoint Medical Initiates Clinical Trial of Nvision VLE Imaging System; Program On Track for Commercial Launch in 2013CAMBRIDGE, Mass.--(BUSINESS WIRE)--NinePoint Medical Initiates Clinical Trial of Nvision VLE Imaging System
>Research and Markets: Fallopian Tube Cancer Global Clinical Trials Review, H2, 2011DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/66eed5/fallopian_tube_can) has announced the addition of GlobalData 's new report "Fallopian Tube Cancer Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Fallopian Tube Cancer Global Clinical Trials Review, H2, 2011" provides data on the Fallopian Tube Cancer clinical trial scenario. This report provides elemental information and data relating to the clinica...
>Research and Markets: Staphylococcus Aureus Infections Global Clinical Trials Review, H2, 2011DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5bdaa9/staphylococcus_aur) has announced the addition of GlobalData's new report "Staphylococcus Aureus Infections Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, "Staphylococcus Aureus Infections Global Clinical Trials Review, H2, 2011," provides data on the Staphylococcus Aureus Infections clinical trial scenario. This report provides elemental informatio...
>Mindchild Medical, Inc. Announces Formation of a Clinical Advisory Board for the MERIDIANTM Line of Non-Invasive Fetal Heart Rate MonitorsNORTH ANDOVER, Mass.--(BUSINESS WIRE)--Mindchild Medical, Inc. today announced formation of a Clinical Advisory Board (CAB) for its MERIDIAN non-invasive fetal heart monitor. The CAB will meet periodically to assess the development strategies for the Meridian Monitor and advise the company on the state of the fetal monitoring market. Adam Wolfberg, MD, currently Chief Medical Officer for Mindchild, will assume the position of Chairman of the CAB immediately. Dr. Wolfberg commented, ?Formation...
>Nearing Goal of 100 Young Investigators, the Prostate Cancer Foundation Expands Global Research EnterpriseSANTA MONICA, Calif.--(BUSINESS WIRE)--Committed to funding the most innovative minds in the field of prostate cancer research, the Prostate Cancer Foundation (PCF) expanded its global knowledge exchange in 2012 and will be expanding its research efforts in new countries later this year. A total of 15 competitive research grants have been awarded to-date in 2012, bringing the total of young investigators awarded to 89. Young Investigator awards are designed to promote long-term careers in the...
>NinePoint Medical Initiates Clinical Trial of Nvision VLE Imaging System; Program On Track for Commercial Launch in 2013CAMBRIDGE, Mass.--(BUSINESS WIRE)--NinePoint Medical Initiates Clinical Trial of Nvision VLE Imaging System
>Research and Markets: Fallopian Tube Cancer Global Clinical Trials Review, H2, 2011DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/66eed5/fallopian_tube_can) has announced the addition of GlobalData 's new report "Fallopian Tube Cancer Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, Fallopian Tube Cancer Global Clinical Trials Review, H2, 2011" provides data on the Fallopian Tube Cancer clinical trial scenario. This report provides elemental information and data relating to the clinica...
>Research and Markets: Staphylococcus Aureus Infections Global Clinical Trials Review, H2, 2011DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5bdaa9/staphylococcus_aur) has announced the addition of GlobalData's new report "Staphylococcus Aureus Infections Global Clinical Trials Review, H2, 2011" to their offering. GlobalData's clinical trial report, "Staphylococcus Aureus Infections Global Clinical Trials Review, H2, 2011," provides data on the Staphylococcus Aureus Infections clinical trial scenario. This report provides elemental informatio...
>Mindchild Medical, Inc. Announces Formation of a Clinical Advisory Board for the MERIDIANTM Line of Non-Invasive Fetal Heart Rate MonitorsNORTH ANDOVER, Mass.--(BUSINESS WIRE)--Mindchild Medical, Inc. today announced formation of a Clinical Advisory Board (CAB) for its MERIDIAN non-invasive fetal heart monitor. The CAB will meet periodically to assess the development strategies for the Meridian Monitor and advise the company on the state of the fetal monitoring market. Adam Wolfberg, MD, currently Chief Medical Officer for Mindchild, will assume the position of Chairman of the CAB immediately. Dr. Wolfberg commented, ?Formation...
Clinical Trials - PR Newswire
>First Vaccine Against Fatal Visceral Leishmaniasis Enters Clinical TrialAs disease expands global reach, Infectious Disease Research Institute teams up with India to target most deadly form of leishmaniasis SEATTLE, Feb. 22, 2012 /PRNewswire-USNewswire/ -- The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by...
>Researchers Publish Long Awaited Lyme Disease and PANDAS Review Despite ControversiesSAN DIEGO, Feb. 22, 2012 /PRNewswire-iReach/ -- Neurologic tics and obsessive-compulsive behaviors caused by a bacterial infection in children were once thought to occur exclusively in PANDAS (Pediatric Autoimmune Disease Associated with Streptococcus infections). Despite ongoing...
>Journal Article Reviews Safety and Efficacy Data for IV Ibuprofen, Advocates Expanded UsageHENDERSONVILLE, Tenn., Feb. 22, 2012 /PRNewswire/ -- Hendersonville Medical Center today announced that anesthesiologist Peter B. Kroll, M.D., has published an article in the January issue of peer-reviewed medical journal Pain Management. The article, titled "Intravenous...
>Inspiration Biopharmaceuticals Highlights Positive Data on its Recombinant Factor IX for People with Hemophilia B Who Have Undergone Major Surgical ProceduresROME, Feb. 22, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced clinical results for the Company's lead product candidate, an intravenous recombinant factor IX (FIX) product being investigated for the treatment and prevention of bleeding in...
>Improved Patient Outcomes, Reduced Hospital Costs With Early Dysphagia DiagnosisNestle Health Science Urges Systematic Screening to Help Improve Outcomes, Decrease Costs FLORHAM PARK, N.J., Feb. 22, 2012 /PRNewswire-USNewswire/ -- It is estimated that up to 75 percent of people experiencing dysphagia – the inability or difficulty to safely swallow...
>First Vaccine Against Fatal Visceral Leishmaniasis Enters Clinical TrialAs disease expands global reach, Infectious Disease Research Institute teams up with India to target most deadly form of leishmaniasis SEATTLE, Feb. 22, 2012 /PRNewswire-USNewswire/ -- The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by...
>Researchers Publish Long Awaited Lyme Disease and PANDAS Review Despite ControversiesSAN DIEGO, Feb. 22, 2012 /PRNewswire-iReach/ -- Neurologic tics and obsessive-compulsive behaviors caused by a bacterial infection in children were once thought to occur exclusively in PANDAS (Pediatric Autoimmune Disease Associated with Streptococcus infections). Despite ongoing...
>Journal Article Reviews Safety and Efficacy Data for IV Ibuprofen, Advocates Expanded UsageHENDERSONVILLE, Tenn., Feb. 22, 2012 /PRNewswire/ -- Hendersonville Medical Center today announced that anesthesiologist Peter B. Kroll, M.D., has published an article in the January issue of peer-reviewed medical journal Pain Management. The article, titled "Intravenous...
>Inspiration Biopharmaceuticals Highlights Positive Data on its Recombinant Factor IX for People with Hemophilia B Who Have Undergone Major Surgical ProceduresROME, Feb. 22, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced clinical results for the Company's lead product candidate, an intravenous recombinant factor IX (FIX) product being investigated for the treatment and prevention of bleeding in...
>Improved Patient Outcomes, Reduced Hospital Costs With Early Dysphagia DiagnosisNestle Health Science Urges Systematic Screening to Help Improve Outcomes, Decrease Costs FLORHAM PARK, N.J., Feb. 22, 2012 /PRNewswire-USNewswire/ -- It is estimated that up to 75 percent of people experiencing dysphagia – the inability or difficulty to safely swallow...
CNN Top Stories
>Opinion: Court to end affirmative action?Abigail Thernstrom says it will be surprising if the Justices are comfortable with declaring affirmative action policy unconstitutional.
>49 killed in Argentina train crashAt least 49 people were killed and more than 600 people were injured when a train plowed into a platform at a Buenos Aires station today, state media said.
>Front-runners mix it up at Arizona forumMitt Romney and Rick Santorum went after each other in the final debate before primaries in Arizona and Michigan -- and before Super Tuesday. FULL STORY
>Obama signs payroll tax deal into lawPresident Barack Obama on Wednesday signed into law the agreement passed by Congress last week to extend the payroll tax cut and unemployment benefits while preventing a cut in payments to Medicare doctors.
>Hitman hired to kill random fur-wearer?A self-proclaimed animal rights activist in Ohio has been charged with soliciting a hit man to kill a random person wearing fur, either by shooting the individual or slitting his or her throat.
>Opinion: Court to end affirmative action?Abigail Thernstrom says it will be surprising if the Justices are comfortable with declaring affirmative action policy unconstitutional.
>49 killed in Argentina train crashAt least 49 people were killed and more than 600 people were injured when a train plowed into a platform at a Buenos Aires station today, state media said.
>Front-runners mix it up at Arizona forumMitt Romney and Rick Santorum went after each other in the final debate before primaries in Arizona and Michigan -- and before Super Tuesday. FULL STORY
>Obama signs payroll tax deal into lawPresident Barack Obama on Wednesday signed into law the agreement passed by Congress last week to extend the payroll tax cut and unemployment benefits while preventing a cut in payments to Medicare doctors.
>Hitman hired to kill random fur-wearer?A self-proclaimed animal rights activist in Ohio has been charged with soliciting a hit man to kill a random person wearing fur, either by shooting the individual or slitting his or her throat.
Contract Pharma
>Boehringer Ingelheim, Xencor in Biosuperiors PactBI to provide antibody manufacturing through Phase I
>OsoBio Appoints Lab DirectorMeyer to manage chemistry and microbiology labs
>Shire Facility Gains EMA Approval for ProductionNew facility increases bioreactor capacity from 1000 to 8000L
>Jubilant HollisterStier Wins Four ContractsWill manufacture sterile parenteral products at Spokane facility
>J&J CEO To Step DownGorsky will take over for Weldon in April
>Boehringer Ingelheim, Xencor in Biosuperiors PactBI to provide antibody manufacturing through Phase I
>OsoBio Appoints Lab DirectorMeyer to manage chemistry and microbiology labs
>Shire Facility Gains EMA Approval for ProductionNew facility increases bioreactor capacity from 1000 to 8000L
>Jubilant HollisterStier Wins Four ContractsWill manufacture sterile parenteral products at Spokane facility
>J&J CEO To Step DownGorsky will take over for Weldon in April
FDA Drugs- What's New
>Comunicado de la FDA sobre la seguridad de los medicamentos: Importantes interacciones entre el medicamento Victrelis (boceprevir) y los medicamentos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavirEl 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) notificó a los profesionales de la salud y a los pacientes que la interacción entre Victrelis (boceprevir), un medicamento inhibidor de la proteasa del virus de hepatitis C (VHC), y ciertos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir (atazanavir, lopinavir, darunavir) tiene el potencial de reducir la eficacia de dichos med...
>Comunicado de la FDA sobre la seguridad de los medicamentos: La diarrea asociada con Clostridum difficile puede estar relacionada con los medicamentos contra la acidez estomacal denominados inhibidores de la bomba de protones (PPIs por sus siglas en inglés)El 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que el uso de medicamentos contra la acidez estomacal conocidos como inhibidores de la bomba de protones (PPIs por sus siglas en inglés), pueden estar relacionados con un riesgo mayor de diarrea asociada con Clostridium difficile (DACD).
>Comunicado de la FDA sobre la seguridad de los medicamentos: La diarrea asociada con Clostridum difficile puede estar relacionada con los medicamentos contra la acidez estomacal denominados inhibidores de la bomba de protones (PPIs por sus siglas en inglés)El 8 de febrero del 2012, la Administraci?e Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en ingl? inform? p?co que el uso de medicamentos contra la acidez estomacal conocidos como inhibidores de la bomba de protones (PPIs por sus siglas en ingl?, pueden estar relacionados con un riesgo mayor de diarrea asociada con Clostridium difficile (DACD).
>FDA Drug Safety Communication: Planned return of CardioGen-82 to market with new Boxed Warning[2-15-2012] The U.S. Food and Drug Administration (FDA) is notifying healthcare professionals; in particular, the medical imaging community, about the planned return of CardioGen-82 to the U.S. market following the voluntary recall by the manufacturer, Bracco Diagnostics, Inc., on July 25, 2011.
>Comunicado de la FDA sobre la seguridad de los medicamentos: Nuevo factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) relacionado con Tysabri (natalizumab)El 20 de enero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que ha identificado como factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) la detección en pruebas de anticuerpos contra el virus JC. PML es una infección poco común pero grave del cerebro relacionada con el uso de Tysabri (natalizumab) para el tratamiento de esclerosis múltiple o enfermedad de Crohn.
>Comunicado de la FDA sobre la seguridad de los medicamentos: Importantes interacciones entre el medicamento Victrelis (boceprevir) y los medicamentos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavirEl 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) notificó a los profesionales de la salud y a los pacientes que la interacción entre Victrelis (boceprevir), un medicamento inhibidor de la proteasa del virus de hepatitis C (VHC), y ciertos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir (atazanavir, lopinavir, darunavir) tiene el potencial de reducir la eficacia de dichos med...
>Comunicado de la FDA sobre la seguridad de los medicamentos: La diarrea asociada con Clostridum difficile puede estar relacionada con los medicamentos contra la acidez estomacal denominados inhibidores de la bomba de protones (PPIs por sus siglas en inglés)El 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que el uso de medicamentos contra la acidez estomacal conocidos como inhibidores de la bomba de protones (PPIs por sus siglas en inglés), pueden estar relacionados con un riesgo mayor de diarrea asociada con Clostridium difficile (DACD).
>Comunicado de la FDA sobre la seguridad de los medicamentos: La diarrea asociada con Clostridum difficile puede estar relacionada con los medicamentos contra la acidez estomacal denominados inhibidores de la bomba de protones (PPIs por sus siglas en inglés)El 8 de febrero del 2012, la Administraci?e Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en ingl? inform? p?co que el uso de medicamentos contra la acidez estomacal conocidos como inhibidores de la bomba de protones (PPIs por sus siglas en ingl?, pueden estar relacionados con un riesgo mayor de diarrea asociada con Clostridium difficile (DACD).
>FDA Drug Safety Communication: Planned return of CardioGen-82 to market with new Boxed Warning[2-15-2012] The U.S. Food and Drug Administration (FDA) is notifying healthcare professionals; in particular, the medical imaging community, about the planned return of CardioGen-82 to the U.S. market following the voluntary recall by the manufacturer, Bracco Diagnostics, Inc., on July 25, 2011.
>Comunicado de la FDA sobre la seguridad de los medicamentos: Nuevo factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) relacionado con Tysabri (natalizumab)El 20 de enero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que ha identificado como factor de riesgo para la leucoencefalopatía multifocal progresiva (PML por sus siglas en inglés) la detección en pruebas de anticuerpos contra el virus JC. PML es una infección poco común pero grave del cerebro relacionada con el uso de Tysabri (natalizumab) para el tratamiento de esclerosis múltiple o enfermedad de Crohn.
FDA News - Business Wire
>The Pacific Northwest's Leading Life Sciences Association Represented at White House Business Council ConferenceSEATTLE--(BUSINESS WIRE)--The Washington Biotechnology & Biomedical Association (WBBA) was represented by Patti McKinnell Davis, Director, Public Affairs, and members of the Pacific Northwest?s life sciences community at the White House Business Council in Washington, DC, on February 9, 2012. The White House Business Council consists of senior officials from the White House and across the Administration who meet regularly with business leaders from around the country. Since April, the White ...
>Erfolgreicher Abschluss der FDA-Prüfung des Biopharmazeutikawerks von EurogentecSERAING, Belgien--(BUSINESS WIRE)--Eurogentec, ein Dienstleistungs- und Vertragsfertigungsunternehmen, gab heute bekannt, dass sich seine Fertigungsanlage für Biopharmazeutika in Seraing (Belgien) kürzlich der Zulassungsprüfung (Pre-Approval Inspection, PAI) der US-amerikanischen Food & Drug Administration (FDA) unterzogen und gemäß den geltenden FDA-Richtlinien den Status ?Akzeptabel? erhalten hat. Mit diesem FDA-Status ist es Eurogentec gestattet, für einen seiner Kunden ein parenteral ver ...
>Riassunto: Lo stabilimento per la produzione di biofarmaci di Eurogentec ha passato con successo l'ispezione statunitense della FDASERAING, Belgio--(BUSINESS WIRE)--Eurogentec, una società per l'assistenza ai clienti e di produzione conto terzi, ha annunciato oggi che il proprio stabilimento per la produzione di medicinali Belgium Drug Substance di Seraing ha recentemente completato la Pre-Approval Inspection (PAI) della U.S. Food & Drug Administration (FDA), ricevendo lo stato "acceptabile" secondo le attuali linee guida della normativa FDA. Questo stato della FDA autorizza Eurogentec a produrre biofarmaci sfusi per us ...
>Dynex Technologies Receives SFDA Approval to Supply DS2 Automated ELISA Processing System to ChinaCHANTILLY, Va.--(BUSINESS WIRE)--Dynex Technologies Receives SFDA Approval to Supply DS2 Automated ELISA Processing System to China. Laboratory automation firm will also establish branch office in Hong Kong.
>Eurogentec's Biologics Facility Successfully Completes US FDA InspectionSERAING, Belgium--(BUSINESS WIRE)--Eurogentec announced today that it has successfully completed a US FDA Pre-Approval Inspection (PAI) and that it will start commercial manufacturing of a biologic for the USA market.
>The Pacific Northwest's Leading Life Sciences Association Represented at White House Business Council ConferenceSEATTLE--(BUSINESS WIRE)--The Washington Biotechnology & Biomedical Association (WBBA) was represented by Patti McKinnell Davis, Director, Public Affairs, and members of the Pacific Northwest?s life sciences community at the White House Business Council in Washington, DC, on February 9, 2012. The White House Business Council consists of senior officials from the White House and across the Administration who meet regularly with business leaders from around the country. Since April, the White ...
>Erfolgreicher Abschluss der FDA-Prüfung des Biopharmazeutikawerks von EurogentecSERAING, Belgien--(BUSINESS WIRE)--Eurogentec, ein Dienstleistungs- und Vertragsfertigungsunternehmen, gab heute bekannt, dass sich seine Fertigungsanlage für Biopharmazeutika in Seraing (Belgien) kürzlich der Zulassungsprüfung (Pre-Approval Inspection, PAI) der US-amerikanischen Food & Drug Administration (FDA) unterzogen und gemäß den geltenden FDA-Richtlinien den Status ?Akzeptabel? erhalten hat. Mit diesem FDA-Status ist es Eurogentec gestattet, für einen seiner Kunden ein parenteral ver ...
>Riassunto: Lo stabilimento per la produzione di biofarmaci di Eurogentec ha passato con successo l'ispezione statunitense della FDASERAING, Belgio--(BUSINESS WIRE)--Eurogentec, una società per l'assistenza ai clienti e di produzione conto terzi, ha annunciato oggi che il proprio stabilimento per la produzione di medicinali Belgium Drug Substance di Seraing ha recentemente completato la Pre-Approval Inspection (PAI) della U.S. Food & Drug Administration (FDA), ricevendo lo stato "acceptabile" secondo le attuali linee guida della normativa FDA. Questo stato della FDA autorizza Eurogentec a produrre biofarmaci sfusi per us ...
>Dynex Technologies Receives SFDA Approval to Supply DS2 Automated ELISA Processing System to ChinaCHANTILLY, Va.--(BUSINESS WIRE)--Dynex Technologies Receives SFDA Approval to Supply DS2 Automated ELISA Processing System to China. Laboratory automation firm will also establish branch office in Hong Kong.
>Eurogentec's Biologics Facility Successfully Completes US FDA InspectionSERAING, Belgium--(BUSINESS WIRE)--Eurogentec announced today that it has successfully completed a US FDA Pre-Approval Inspection (PAI) and that it will start commercial manufacturing of a biologic for the USA market.
FDA Press Releases
>Federal government gains permanent injunction against raw milk producerA federal court has granted the U.S. Food and Drug Administration a permanent injunction preventing Daniel L. Allgyer and his Rainbow Acres Farm from distributing raw milk and raw milk products in final package form for human consumption across state lines.
>FDA acts to bolster supply of critically needed cancer drugsThe U.S. Food and Drug Administration today announced a series of steps to increase the supply of critically needed cancer drugs and build on President Obama?s Executive Order to help prevent future drug shortages.
>FDA approves Korlym for patients with endogenous Cushing's syndromeToday, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing?s syndrome. This drug was approved for use in patients with endogenous Cushing?s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Korlym should never be used (contraindicated) by pregnant women.
>FDA approves Korlym for patients with endogenous Cushing’s syndromeToday, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing’s syndrome. This drug was approved for use in patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Korlym should never be used (contraindicated) by pregnant women.
>FDA approves Zioptan to treat elevated eye pressureOn February 10, the U.S. Food and Drug Administration approved Zioptan (tafluprost ophthalmic solution) to help reduce elevated eye pressure in people with open-angle glaucoma.
>Federal government gains permanent injunction against raw milk producerA federal court has granted the U.S. Food and Drug Administration a permanent injunction preventing Daniel L. Allgyer and his Rainbow Acres Farm from distributing raw milk and raw milk products in final package form for human consumption across state lines.
>FDA acts to bolster supply of critically needed cancer drugsThe U.S. Food and Drug Administration today announced a series of steps to increase the supply of critically needed cancer drugs and build on President Obama?s Executive Order to help prevent future drug shortages.
>FDA approves Korlym for patients with endogenous Cushing's syndromeToday, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing?s syndrome. This drug was approved for use in patients with endogenous Cushing?s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Korlym should never be used (contraindicated) by pregnant women.
>FDA approves Korlym for patients with endogenous Cushing’s syndromeToday, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing’s syndrome. This drug was approved for use in patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Korlym should never be used (contraindicated) by pregnant women.
>FDA approves Zioptan to treat elevated eye pressureOn February 10, the U.S. Food and Drug Administration approved Zioptan (tafluprost ophthalmic solution) to help reduce elevated eye pressure in people with open-angle glaucoma.
FDA Vaccines, Blood and Biologics - What's New
>Cord Blood Banking Information for Consumers
>Cord Blood Banking – Information for Consumers
>Cord Blood Banking ââ?¬â?? Information for Consumers
>Influenza Virus Vaccine for the 2011 - 2012 SeasonCumulative 2010/2011 Season Lot Release Status (Updated 10/20/2010)
>Fluzone, Fluzone High-Dose and Fluzone Intradermal
>Cord Blood Banking Information for Consumers
>Cord Blood Banking – Information for Consumers
>Cord Blood Banking ââ?¬â?? Information for Consumers
>Influenza Virus Vaccine for the 2011 - 2012 SeasonCumulative 2010/2011 Season Lot Release Status (Updated 10/20/2010)
>Fluzone, Fluzone High-Dose and Fluzone Intradermal
FierceBiotech
>FDA panel overwhelmingly backs Vivus' diet drugWho said this panel vote would be close? Non-agency experts gave strong support to Vivus' ($VVUS) quest to gain FDA approval for its diet pill Qnexa, voting 20-2 this afternoon to support the drug getting a green light to hit the U.S. market, TheStreet reported. The Endocrinologic and Metabolic Drugs Advisory Committee vote comes ahead of the FDA's decision, which is expected by April 17, on whether to stamp an approval on the Mountain View, CA-based developer's drug. If approved, Qnexa woul...
>Genomics revolution ignites new M&A talk, showstoppersRoche's $5.7 billion hostile bid to scoop up DNA sequencing machine maker Illumina ($ILMN) has triggered talk of further merger targets in the promising genomics arena. And the race to invent faster and cheaper ways of decoding the genome has pushed small companies to the cutting edge of the field, giving industry leaders such as Illumina and Life Technologies ($LIFE) a run for their money. While Swiss drug giant Roche continues its advance to gobble up a resistant Illumina, analysts have not...
>Eisai co-developing cancer drug fueled by bacteria; U.S. trials launch soon Tokyo's Anaeropharma Science is launching U.S. clinical trials as early as March for a new stomach cancer drug fueled by bacteria. The biotech is partnering with Japanese drug giant Eisai to bring the treatment to market, according to the Daily Yomiuri. Testing will involve 60 patients over 3 ½ years. Anaeropharma loads the drug with bifidobacteria, which helps the drug both reach and build up within its tumor target because it is drawn to environments lacking oxygen, just like solid tumors. ...
>Collegium Pharma scores $22M round for abuse-preventing painkiller in Phase IIIVenture backers have rallied behind Collegium Pharmaceutical to continue a late-stage trial for its extended-release version of oxycodone. The investors--led by Longitude Capital and Skyline Ventures, and including Frazier Healthcare Ventures and Boston Millennia Partners--are betting $22.5 million in the developer's Series B round. With traditional oxycodone offering a recipe for abuse, Collegium has a proprietary formulation of the popular pain drug dubbed COL-003 that aims to thwart the ty...
>Venture backer makes $7M bet on cardio drug tech that could rival stentsWith drug delivery tech from a children's hospital in Philadelphia, Vascular Magnetics has pocketed a $7 million Series A round from lone investor Devon Park Bioventures. And the startup has ambitious plans to advance magnetic drug-loaded particles for the huge market to treat peripheral artery disease--offering a potential alternative to a range of existing interventions against the disease that affects some 10 million Americans, according to the company. The startup's tech is based on the p...
>FDA panel overwhelmingly backs Vivus' diet drugWho said this panel vote would be close? Non-agency experts gave strong support to Vivus' ($VVUS) quest to gain FDA approval for its diet pill Qnexa, voting 20-2 this afternoon to support the drug getting a green light to hit the U.S. market, TheStreet reported. The Endocrinologic and Metabolic Drugs Advisory Committee vote comes ahead of the FDA's decision, which is expected by April 17, on whether to stamp an approval on the Mountain View, CA-based developer's drug. If approved, Qnexa woul...
>Genomics revolution ignites new M&A talk, showstoppersRoche's $5.7 billion hostile bid to scoop up DNA sequencing machine maker Illumina ($ILMN) has triggered talk of further merger targets in the promising genomics arena. And the race to invent faster and cheaper ways of decoding the genome has pushed small companies to the cutting edge of the field, giving industry leaders such as Illumina and Life Technologies ($LIFE) a run for their money. While Swiss drug giant Roche continues its advance to gobble up a resistant Illumina, analysts have not...
>Eisai co-developing cancer drug fueled by bacteria; U.S. trials launch soon Tokyo's Anaeropharma Science is launching U.S. clinical trials as early as March for a new stomach cancer drug fueled by bacteria. The biotech is partnering with Japanese drug giant Eisai to bring the treatment to market, according to the Daily Yomiuri. Testing will involve 60 patients over 3 ½ years. Anaeropharma loads the drug with bifidobacteria, which helps the drug both reach and build up within its tumor target because it is drawn to environments lacking oxygen, just like solid tumors. ...
>Collegium Pharma scores $22M round for abuse-preventing painkiller in Phase IIIVenture backers have rallied behind Collegium Pharmaceutical to continue a late-stage trial for its extended-release version of oxycodone. The investors--led by Longitude Capital and Skyline Ventures, and including Frazier Healthcare Ventures and Boston Millennia Partners--are betting $22.5 million in the developer's Series B round. With traditional oxycodone offering a recipe for abuse, Collegium has a proprietary formulation of the popular pain drug dubbed COL-003 that aims to thwart the ty...
>Venture backer makes $7M bet on cardio drug tech that could rival stentsWith drug delivery tech from a children's hospital in Philadelphia, Vascular Magnetics has pocketed a $7 million Series A round from lone investor Devon Park Bioventures. And the startup has ambitious plans to advance magnetic drug-loaded particles for the huge market to treat peripheral artery disease--offering a potential alternative to a range of existing interventions against the disease that affects some 10 million Americans, according to the company. The startup's tech is based on the p...
FierceBiotech IT
>Google software could aid drug designChemists have tapped core Google ($GOOG) software for measuring the importance of web pages to study the shape and organization of molecules. The researchers' adapted version of Google's PageRank algorithms have enabled them to computerize experiments that might otherwise be conducted in physical labs. The group's software marks an interesting convergence of molecular chemistry and search engine tech, one that might not have been considered back when Google founders Sergey Brin and Larry Page...
>Big Pharma activity eyed in mobile trendsThe life sciences industry could drive at least a couple trends this year in the mobile tech arena, according to mobihealthnews. In a roundup of a dozen trends to watch this year, the publication says the FDA could publish guidelines on how medical device regulations are translated into the realm of mobile devices such as smartphones and tablets. Also, mobile tech is expected to aid pharma groups in the areas of advertising, clinical development (such as Pfizer's ($PFE) eclinical trial) and g...
>Oracle aids Moffitt Cancer Center's IT system for speeding patient recruitmentSlow patient recruitment looms as one of the biopharma industry's most notorious boogiemen, delaying the start of trials and prolonging the costly development process. Moffitt Cancer Center in Tampa, FL, aims to slay this trials monster with its patented computer system that streamlines recruitment into cancer drug studies. Moffitt won a U.S. patent for the computer system, the group announced last week. The system enables the center to, among other things, match the molecular profile of a pa...
>Global Alzheimer's researchers seek cloud-based infrastructure to share dataWith Alzheimer's disease threatening millions of patients worldwide, the European Commission-funded database that stores 3-D brain scans in the cloud has gained global attention. The so-called neuGRID, which has been tested in Europe, is seeking partners in North America and Asia to support sharing of Alzheimer's data around the world. The goal is to speed diagnosis of the memory-stealing illness. Work is afoot to advance a global version of neuGRID dubbed outGRID, and stakeholders from the E...
>Inside dope on one of biopharma's hottest job markets Got biopharma job jitters? If so, you're not alone; 44% of pharma workers are worried about getting the ax, according to a PharmaIQ survey. Yet there are some bright spots in the market for life sciences jobs, and one area of acute demand has been in bioinformatics. Corporate recruiter Rick von Rueden gave FierceBiotech IT the lowdown on opportunities in this hot field. "There has certainly been a rapidly rising upward slope of demand for experienced leaders in bioinformatics, and that includ...
>Google software could aid drug designChemists have tapped core Google ($GOOG) software for measuring the importance of web pages to study the shape and organization of molecules. The researchers' adapted version of Google's PageRank algorithms have enabled them to computerize experiments that might otherwise be conducted in physical labs. The group's software marks an interesting convergence of molecular chemistry and search engine tech, one that might not have been considered back when Google founders Sergey Brin and Larry Page...
>Big Pharma activity eyed in mobile trendsThe life sciences industry could drive at least a couple trends this year in the mobile tech arena, according to mobihealthnews. In a roundup of a dozen trends to watch this year, the publication says the FDA could publish guidelines on how medical device regulations are translated into the realm of mobile devices such as smartphones and tablets. Also, mobile tech is expected to aid pharma groups in the areas of advertising, clinical development (such as Pfizer's ($PFE) eclinical trial) and g...
>Oracle aids Moffitt Cancer Center's IT system for speeding patient recruitmentSlow patient recruitment looms as one of the biopharma industry's most notorious boogiemen, delaying the start of trials and prolonging the costly development process. Moffitt Cancer Center in Tampa, FL, aims to slay this trials monster with its patented computer system that streamlines recruitment into cancer drug studies. Moffitt won a U.S. patent for the computer system, the group announced last week. The system enables the center to, among other things, match the molecular profile of a pa...
>Global Alzheimer's researchers seek cloud-based infrastructure to share dataWith Alzheimer's disease threatening millions of patients worldwide, the European Commission-funded database that stores 3-D brain scans in the cloud has gained global attention. The so-called neuGRID, which has been tested in Europe, is seeking partners in North America and Asia to support sharing of Alzheimer's data around the world. The goal is to speed diagnosis of the memory-stealing illness. Work is afoot to advance a global version of neuGRID dubbed outGRID, and stakeholders from the E...
>Inside dope on one of biopharma's hottest job markets Got biopharma job jitters? If so, you're not alone; 44% of pharma workers are worried about getting the ax, according to a PharmaIQ survey. Yet there are some bright spots in the market for life sciences jobs, and one area of acute demand has been in bioinformatics. Corporate recruiter Rick von Rueden gave FierceBiotech IT the lowdown on opportunities in this hot field. "There has certainly been a rapidly rising upward slope of demand for experienced leaders in bioinformatics, and that includ...
FierceBiotech Research
>Mouse cardiac stem cells helped repair rodents' heart attack damageIt may be possible someday to use a patient's own cardiac stem cells to minimize or even repair the damage after a heart attack. University of California-San Francisco scientists believe that this process is possible after generating promising results in mice. Details are published online in the journal PLoS One. For this study to begin, some poor, middle-aged mice had to have heart attacks. (They did.) At that point, researchers isolated Sca-1+ cardiac stem cells from all four chambers of th...
>Engineered measles virus prolongs lifespan of brain cancer-stricken miceScientists are testing an engineered measles virus as a cancer weapon. Absorb that thought first: Something so threatening on its own can be used to a better purpose. And now consider the specifics: Researchers working together from three institutions anticipate a Phase I clinical trial in humans in the coming months to test their measles virus--dubbed MV-GSP--to treat deadly medulloblastoma brain tumors. That news comes as the altered virus virtually doubled the lifespans of mice infected wi...
>Can omega-3 fatty acids beat back cancer? Maybe notLet the fight continue to rage over whether drugs and supplements made from omega-3 fatty acids have any therapeutic effect. We’ve told you about recent research that suggests that fish oil and walnuts (both of which have omega-3s) could combat leukemia and reduce the risk of prostate cancer, respectively, and form the basis of potential new drugs. Now comes a potentially contradictory French study that is far from conclusive on the matter. The study looked at Vitamin B and omega-3 supp...
>Flu, over time, could increase Alzheimer's vulnerability The flu and herpes viruses are bad enough already. But Harvard Medical School scientists believe that they may cause lasting brain cell damage, making sufferers vulnerable to neurodegenerative diseases like Alzheimer's and Parkinson's. Details are published in the journal Science Translational Medicine. A MyHealthNewsDaily article, via FoxNews.com, offers some pretty solid highlights of the main findings. Researchers think the key here is inflammation, according to the article--specifically i...
>Amniotic stem cells boost kidney disease survival timeResearchers at Children's Hospital Los Angeles say they've successfully tested a surprisingly simple treatment to slow the progression of kidney disease: an injection of stem cells derived from amniotic fluid. Roger De Filippo and Laura Perin pursued the experiment using an Alport's Syndrome model--a kidney disease involving progressively worsening fibrosis. Their team injected stem cells that came from the fluid around the fetus at an early stage of the disease. The group found that the trea...
>Mouse cardiac stem cells helped repair rodents' heart attack damageIt may be possible someday to use a patient's own cardiac stem cells to minimize or even repair the damage after a heart attack. University of California-San Francisco scientists believe that this process is possible after generating promising results in mice. Details are published online in the journal PLoS One. For this study to begin, some poor, middle-aged mice had to have heart attacks. (They did.) At that point, researchers isolated Sca-1+ cardiac stem cells from all four chambers of th...
>Engineered measles virus prolongs lifespan of brain cancer-stricken miceScientists are testing an engineered measles virus as a cancer weapon. Absorb that thought first: Something so threatening on its own can be used to a better purpose. And now consider the specifics: Researchers working together from three institutions anticipate a Phase I clinical trial in humans in the coming months to test their measles virus--dubbed MV-GSP--to treat deadly medulloblastoma brain tumors. That news comes as the altered virus virtually doubled the lifespans of mice infected wi...
>Can omega-3 fatty acids beat back cancer? Maybe notLet the fight continue to rage over whether drugs and supplements made from omega-3 fatty acids have any therapeutic effect. We’ve told you about recent research that suggests that fish oil and walnuts (both of which have omega-3s) could combat leukemia and reduce the risk of prostate cancer, respectively, and form the basis of potential new drugs. Now comes a potentially contradictory French study that is far from conclusive on the matter. The study looked at Vitamin B and omega-3 supp...
>Flu, over time, could increase Alzheimer's vulnerability The flu and herpes viruses are bad enough already. But Harvard Medical School scientists believe that they may cause lasting brain cell damage, making sufferers vulnerable to neurodegenerative diseases like Alzheimer's and Parkinson's. Details are published in the journal Science Translational Medicine. A MyHealthNewsDaily article, via FoxNews.com, offers some pretty solid highlights of the main findings. Researchers think the key here is inflammation, according to the article--specifically i...
>Amniotic stem cells boost kidney disease survival timeResearchers at Children's Hospital Los Angeles say they've successfully tested a surprisingly simple treatment to slow the progression of kidney disease: an injection of stem cells derived from amniotic fluid. Roger De Filippo and Laura Perin pursued the experiment using an Alport's Syndrome model--a kidney disease involving progressively worsening fibrosis. Their team injected stem cells that came from the fluid around the fetus at an early stage of the disease. The group found that the trea...
FiercePharma
>Teva wraps up most propofol suits for $285MTeva Pharmaceutical Industries ($TEVA) is closing in on the last chapter of its propofol litigation. The Israeli drugmaker will pay $285 million to wrap up most of the liability suits spawned by a hepatitis C outbreak, leaving just 15 cases open. The deal comes as Teva was fighting its fourth bellwether suit--and after juries in the first three trials pummeled the drugmaker with extremely hefty damages. Teva has been defending itself against allegations that its propofol packaging--in vials l...
>Biotech investors collect a fraction of milestone cashWith pharma's biotech buyouts increasingly light on up-front cash and heavy on milestone payments, investors are collecting less money from M&A deals. Only 24% of milestone money actually changed hands in deals made from January 2005 through December 2009. Report
>J&J picks Gorsky over McCoy to fill CEO's seatIt wasn't exactly a surprise, Johnson & Johnson's ($JNJ) choice of Vice Chair Alex Gorsky to succeed William Weldon as CEO. Gorsky has been one of the two apparent front-runners for the job ever since he and Sheri McCoy were elevated to their current roles in December 2010. But McCoy was considered in some circles to be the favorite for the top job. And Gorsky's appointment raised questions even as analysts hailed him as "the natural choice." Gorsky has spent most of his business career at J&...
>Mexico's Genomma lodges $834M bid for PrestigeA Mexican drugmaker aims to snap up the consumer products company Prestige Brands in a deal valued at almost $850 million. Genomma Lab, based in Mexico City, offered $16.60 per share for the U.S.-based company, which makes household cleansers, contact lens solutions, and over-the-counter remedies such as Compound W wart remover. Prestige said it was surprised by the offer, made by Genomma without an initial approach to management. "We are puzzled by Genomma Lab's decision to go public without...
>Shire to boost Vpriv, Replagal with EMA-approved plantShire's rare-disease challenge is heating up. The company won European approval for a U.S. plant slated to produce Vpriv, a Gaucher disease treatment that aims to rival Genzyme's Cerezyme. The facility is still awaiting FDA approval, but it's another charge forward for Shire in its joust for market share. The approval not only will create new capacity for Vpriv, but promises to open up space for increased production of Replagal, another drug that could steal scripts from Genzyme. Replagal tre...
>Teva wraps up most propofol suits for $285MTeva Pharmaceutical Industries ($TEVA) is closing in on the last chapter of its propofol litigation. The Israeli drugmaker will pay $285 million to wrap up most of the liability suits spawned by a hepatitis C outbreak, leaving just 15 cases open. The deal comes as Teva was fighting its fourth bellwether suit--and after juries in the first three trials pummeled the drugmaker with extremely hefty damages. Teva has been defending itself against allegations that its propofol packaging--in vials l...
>Biotech investors collect a fraction of milestone cashWith pharma's biotech buyouts increasingly light on up-front cash and heavy on milestone payments, investors are collecting less money from M&A deals. Only 24% of milestone money actually changed hands in deals made from January 2005 through December 2009. Report
>J&J picks Gorsky over McCoy to fill CEO's seatIt wasn't exactly a surprise, Johnson & Johnson's ($JNJ) choice of Vice Chair Alex Gorsky to succeed William Weldon as CEO. Gorsky has been one of the two apparent front-runners for the job ever since he and Sheri McCoy were elevated to their current roles in December 2010. But McCoy was considered in some circles to be the favorite for the top job. And Gorsky's appointment raised questions even as analysts hailed him as "the natural choice." Gorsky has spent most of his business career at J&...
>Mexico's Genomma lodges $834M bid for PrestigeA Mexican drugmaker aims to snap up the consumer products company Prestige Brands in a deal valued at almost $850 million. Genomma Lab, based in Mexico City, offered $16.60 per share for the U.S.-based company, which makes household cleansers, contact lens solutions, and over-the-counter remedies such as Compound W wart remover. Prestige said it was surprised by the offer, made by Genomma without an initial approach to management. "We are puzzled by Genomma Lab's decision to go public without...
>Shire to boost Vpriv, Replagal with EMA-approved plantShire's rare-disease challenge is heating up. The company won European approval for a U.S. plant slated to produce Vpriv, a Gaucher disease treatment that aims to rival Genzyme's Cerezyme. The facility is still awaiting FDA approval, but it's another charge forward for Shire in its joust for market share. The approval not only will create new capacity for Vpriv, but promises to open up space for increased production of Replagal, another drug that could steal scripts from Genzyme. Replagal tre...
FiercePharma Manufacturing
>Leader of Pakistan drugmakers resigns in frustrationThe acting chief of the Pakistan Pharmaceutical Manufacturers Association has resigned from the organization in outrage over a drug scandal that has cost more than 130 lives. And consultant Robert Walsh, who went to Pakistan twice last year to survey its pharmaceutical industry, says he understands why Tariq Ikram stepped down. Walsh, whose Samsara Biopharma Consulting does business development and due diligence for international biotech pharmaceutical companies, said his visit confirmed the ...
>UPDATED: Novartis suspends production at another plantNovartis ($NVS) appears to be having a tough time getting its act together as far as the FDA's view of manufacturing standards go. The company's Sandoz unit reported last week that production of some of its drugs at a plant in Boucherville, Quebec, Canada, had been suspended because remediation efforts there required it stop production lines. Novartis Consumer Health is still grappling with issues at a plant in Lincoln, NE, that was closed because of a long list of FDA observations. In a le...
>VP of China shows up for signing of Pfizer, Hisun dealIt is not often the signing of a document that is still short of a joint venture agreement attracts a host of dignitaries, but that is what happened with Pfizer ($PFE) and Chinese pharmaceutical company Zhejiang Hisun Pharmaceutical. The signing of a "framework" agreement was held at the Sino-U.S. Economy & Trade Forum in Los Angeles during the visit of Xi Jinping, the vice president of China. Xi Jinping attended the event, as did U.S. Secretary of Commerce John Bryson and other officials fro...
>Hospira on track with expansions in IndiaHospira ($HSP) has a lot going on related to manufacturing, but it seems all of the attention is focused on improvements under way at its troubled plants in North Carolina and Texas. Indeed, so much time was spent during last week's earnings call on Hospira's work to address FDA 483 complaints at plants in Rocky Mount, NC, and Austin, TX, that little was devoted to significant manufacturing expansions in India. The Rocky Mount plant, which closed in December, resumed production in January, an...
>Novartis halts production at another plantNovartis ($NVS) appears to be having a tough time getting its act together as far as the FDA's view of manufacturing standards go. The company's Sandoz unit reported last week that production of some of its drugs at a plant in Boucherville, Quebec, Canada, had been suspended because remediation efforts there required it stop production lines. Novartis Consumer Health is still grappling with issues at a plant in Lincoln, NE, that was closed because of a long list of FDA observations. In a le...
>Leader of Pakistan drugmakers resigns in frustrationThe acting chief of the Pakistan Pharmaceutical Manufacturers Association has resigned from the organization in outrage over a drug scandal that has cost more than 130 lives. And consultant Robert Walsh, who went to Pakistan twice last year to survey its pharmaceutical industry, says he understands why Tariq Ikram stepped down. Walsh, whose Samsara Biopharma Consulting does business development and due diligence for international biotech pharmaceutical companies, said his visit confirmed the ...
>UPDATED: Novartis suspends production at another plantNovartis ($NVS) appears to be having a tough time getting its act together as far as the FDA's view of manufacturing standards go. The company's Sandoz unit reported last week that production of some of its drugs at a plant in Boucherville, Quebec, Canada, had been suspended because remediation efforts there required it stop production lines. Novartis Consumer Health is still grappling with issues at a plant in Lincoln, NE, that was closed because of a long list of FDA observations. In a le...
>VP of China shows up for signing of Pfizer, Hisun dealIt is not often the signing of a document that is still short of a joint venture agreement attracts a host of dignitaries, but that is what happened with Pfizer ($PFE) and Chinese pharmaceutical company Zhejiang Hisun Pharmaceutical. The signing of a "framework" agreement was held at the Sino-U.S. Economy & Trade Forum in Los Angeles during the visit of Xi Jinping, the vice president of China. Xi Jinping attended the event, as did U.S. Secretary of Commerce John Bryson and other officials fro...
>Hospira on track with expansions in IndiaHospira ($HSP) has a lot going on related to manufacturing, but it seems all of the attention is focused on improvements under way at its troubled plants in North Carolina and Texas. Indeed, so much time was spent during last week's earnings call on Hospira's work to address FDA 483 complaints at plants in Rocky Mount, NC, and Austin, TX, that little was devoted to significant manufacturing expansions in India. The Rocky Mount plant, which closed in December, resumed production in January, an...
>Novartis halts production at another plantNovartis ($NVS) appears to be having a tough time getting its act together as far as the FDA's view of manufacturing standards go. The company's Sandoz unit reported last week that production of some of its drugs at a plant in Boucherville, Quebec, Canada, had been suspended because remediation efforts there required it stop production lines. Novartis Consumer Health is still grappling with issues at a plant in Lincoln, NE, that was closed because of a long list of FDA observations. In a le...
FierceVaccines
>UPDATED: Research paving way to salmonella vaccineSalmonella is a bacteria found in both humans and animals. It causes food poisoning, and infections can be particularly dangerous in children and the elderly. Antibiotics are becoming ineffective against salmonella, and a vaccine could protect against even the resistant forms. A team of researchers from institutions in the U.S., Europe and Africa, including the Novartis Vaccines Institute for Global Health, created an array of 2,700 proteins that make up about 60% of all the proteins in the s...
>Research paving way to salmonella vaccineSalmonella is a bacteria found in both humans and animals. It causes food poisoning, and infections can be particularly dangerous in children and the elderly. Antibiotics are becoming ineffective against salmonella, and a vaccine could protect against even the resistant forms. A team of researchers from institutions in the U.S., Europe and Africa, including the Novartis Vaccines Institute for Global Health, created an array of 2,700 proteins that make up about 60% of all the proteins in the s...
>FDA says no to Novartis' Menveo vax for babies Novartis ($NVS) has suffered a setback in its effort to expand the use of Menveo, its quadrivalent meningococcal conjugate vaccine. The FDA has turned down its application to extend the approval to infants and toddlers ages 2 months to 2 years. Novartis submitted a supplemental biologics license application (sBLA) in April, and the FDA has come back with a complete response letter asking for answers to additional questions. While it's not yet clear what additional information is needed, Novar...
>IIL developing firsts for vaccines in IndiaChikungunya and Japanese encephalitis virus (JEV) are both mosquito-borne viruses, and Indian Immunologicals Limited is working on what could be the world's first chikungunya vaccine, as well as India's first live JEV vaccine. The vaccines are both in preclinical trials, and the India-based company expects to start clinical studies in this year or next, with vaccines on the market by 2014 or 2015. Chikungunya causes fever and joint pain, as well as muscle pain, headache and tiredness. It is m...
>FDA says no to Novartis' Menveo for babies Novartis ($NVS) has suffered a setback in its effort to expand the use of Menveo, its quadrivalent meningococcal conjugate vaccine. The FDA has turned down its application to extend the approval to infants and toddlers ages 2 months to 2 years. Novartis submitted a supplemental biologics license application (sBLA) in April, and the FDA has come back with a complete response letter asking for answers to additional questions. While it's not yet clear what additional information is needed, Novar...
>UPDATED: Research paving way to salmonella vaccineSalmonella is a bacteria found in both humans and animals. It causes food poisoning, and infections can be particularly dangerous in children and the elderly. Antibiotics are becoming ineffective against salmonella, and a vaccine could protect against even the resistant forms. A team of researchers from institutions in the U.S., Europe and Africa, including the Novartis Vaccines Institute for Global Health, created an array of 2,700 proteins that make up about 60% of all the proteins in the s...
>Research paving way to salmonella vaccineSalmonella is a bacteria found in both humans and animals. It causes food poisoning, and infections can be particularly dangerous in children and the elderly. Antibiotics are becoming ineffective against salmonella, and a vaccine could protect against even the resistant forms. A team of researchers from institutions in the U.S., Europe and Africa, including the Novartis Vaccines Institute for Global Health, created an array of 2,700 proteins that make up about 60% of all the proteins in the s...
>FDA says no to Novartis' Menveo vax for babies Novartis ($NVS) has suffered a setback in its effort to expand the use of Menveo, its quadrivalent meningococcal conjugate vaccine. The FDA has turned down its application to extend the approval to infants and toddlers ages 2 months to 2 years. Novartis submitted a supplemental biologics license application (sBLA) in April, and the FDA has come back with a complete response letter asking for answers to additional questions. While it's not yet clear what additional information is needed, Novar...
>IIL developing firsts for vaccines in IndiaChikungunya and Japanese encephalitis virus (JEV) are both mosquito-borne viruses, and Indian Immunologicals Limited is working on what could be the world's first chikungunya vaccine, as well as India's first live JEV vaccine. The vaccines are both in preclinical trials, and the India-based company expects to start clinical studies in this year or next, with vaccines on the market by 2014 or 2015. Chikungunya causes fever and joint pain, as well as muscle pain, headache and tiredness. It is m...
>FDA says no to Novartis' Menveo for babies Novartis ($NVS) has suffered a setback in its effort to expand the use of Menveo, its quadrivalent meningococcal conjugate vaccine. The FDA has turned down its application to extend the approval to infants and toddlers ages 2 months to 2 years. Novartis submitted a supplemental biologics license application (sBLA) in April, and the FDA has come back with a complete response letter asking for answers to additional questions. While it's not yet clear what additional information is needed, Novar...
Health News - BizJournals.com
>UnitedHealth Group executive elected to Xcel Energy boardGail Koziara Boudreaux, CEO of a subsidiary of UnitedHealth Group Inc., has been elected to the board of Xcel Energy Inc. Boudreaux, 51, is CEO of UnitedHealthcare and manages businesses that represent 93 percent of the revenue created by Minnetonka-based UnitedHealth (NYSE: UNH). She has been named to Fortune magazine's list of the "50 Most Powerful Women in Business" several times and was honored by the Minneapolis/St. Paul Business Journal with a Women in Business "Industry Leader" a...
>Prime Healthcare Services buys Phila.-area hospitalPrime Healthcare Services acquired Roxborough Memorial Hospital from Solis Healthcare Wednesday. Terms of the deal were not disclosed. Roxborough Memorial, a 140-bed hospital in the northwest section of Philadelphia, was formerly part of Tenet Health Corp. of Dallas before it was sold to Solis Healthcare, a for-profit hospital management firm based in the city, in August 2007. Solis also bought Warminster Hospital from Tenet, but then sold the Bucks County medical center to Abington Mem...
>Supreme Court sends Medi-Cal fee suit back to Court of AppealsThe U.S. Supreme Court tossed the California lawsuit over a proposed 10 percent cut to Medi-Cal provider fees back to the Ninth Circuit Court of Appeals Wednesday, paving the way for further legal argument at that level. The Ninth Circuit previously sided with doctors and other providers, agreeing they should have the ability to sue to block the cuts. The ruling is narrow one that cites the complexity of the issue and changes since the first lawsuit was filed and lobs the case back to t...
>High Point Regional exploring alliance with another health systemHigh Point Regional Health System is looking into the possibility of aligning with another health system. The health system?s Board of Trustees on Tuesday approved moving to investigate ?strategic alignments.? In an announcement, hospital officials cited the constantly changing health care environment, the increase in capital needs and ongoing effects of health care reform as reasons for considering all potential alignments in an effort to remain financially healthy and accommodate the ...
>Brownback's Medicaid reform program lures five insurer bidsFive insurance companies have submitted bids to participate in KanCare, Gov. Sam Brownback?s effort to remodel the state?s Medicaid program. Announced Wednesday, the five are competing for three spots to oversee the program, which seeks to replace the current state-run operation with a private ?managed care? model. The five are WellCare of Kansas, based in Tampa, Fla.; Sunflower State Health Plan, based in Topeka; United Health Care, based in Minneapolis; Coventry Health Care of Kansas,...
>UnitedHealth Group executive elected to Xcel Energy boardGail Koziara Boudreaux, CEO of a subsidiary of UnitedHealth Group Inc., has been elected to the board of Xcel Energy Inc. Boudreaux, 51, is CEO of UnitedHealthcare and manages businesses that represent 93 percent of the revenue created by Minnetonka-based UnitedHealth (NYSE: UNH). She has been named to Fortune magazine's list of the "50 Most Powerful Women in Business" several times and was honored by the Minneapolis/St. Paul Business Journal with a Women in Business "Industry Leader" a...
>Prime Healthcare Services buys Phila.-area hospitalPrime Healthcare Services acquired Roxborough Memorial Hospital from Solis Healthcare Wednesday. Terms of the deal were not disclosed. Roxborough Memorial, a 140-bed hospital in the northwest section of Philadelphia, was formerly part of Tenet Health Corp. of Dallas before it was sold to Solis Healthcare, a for-profit hospital management firm based in the city, in August 2007. Solis also bought Warminster Hospital from Tenet, but then sold the Bucks County medical center to Abington Mem...
>Supreme Court sends Medi-Cal fee suit back to Court of AppealsThe U.S. Supreme Court tossed the California lawsuit over a proposed 10 percent cut to Medi-Cal provider fees back to the Ninth Circuit Court of Appeals Wednesday, paving the way for further legal argument at that level. The Ninth Circuit previously sided with doctors and other providers, agreeing they should have the ability to sue to block the cuts. The ruling is narrow one that cites the complexity of the issue and changes since the first lawsuit was filed and lobs the case back to t...
>High Point Regional exploring alliance with another health systemHigh Point Regional Health System is looking into the possibility of aligning with another health system. The health system?s Board of Trustees on Tuesday approved moving to investigate ?strategic alignments.? In an announcement, hospital officials cited the constantly changing health care environment, the increase in capital needs and ongoing effects of health care reform as reasons for considering all potential alignments in an effort to remain financially healthy and accommodate the ...
>Brownback's Medicaid reform program lures five insurer bidsFive insurance companies have submitted bids to participate in KanCare, Gov. Sam Brownback?s effort to remodel the state?s Medicaid program. Announced Wednesday, the five are competing for three spots to oversee the program, which seeks to replace the current state-run operation with a private ?managed care? model. The five are WellCare of Kansas, based in Tampa, Fla.; Sunflower State Health Plan, based in Topeka; United Health Care, based in Minneapolis; Coventry Health Care of Kansas,...
Health News - CNBC
>Colon cancer study backs blood stool screening test
>Allscripts CEO Talks High Tech TurnaroundGlen Tullman, Allscripts CEO, discusses the shift to electronic medical records and how his company is poised to profit from it, with Mad Money's Jim Cramer.
>Prevnar trial results needed for CDC recommendation
>Express Scripts 4Q profit falls 12 percentPharmacy benefits manager Express Scripts Inc. said Wednesday its profit fell 12 percent in the fourth quarter, mostly on costs related to its proposed acquisition of competitor Medco Health Solutions Inc.
>Factbox: Winners, losers in Obama corporate tax planThe Obama administration on Wednesday proposed a plan to revamp the U.S. corporate tax system, slashing the top tax rate to 28 percent, while eliminating many loopholes that companies rely on to cut their taxes.
>Colon cancer study backs blood stool screening test
>Allscripts CEO Talks High Tech TurnaroundGlen Tullman, Allscripts CEO, discusses the shift to electronic medical records and how his company is poised to profit from it, with Mad Money's Jim Cramer.
>Prevnar trial results needed for CDC recommendation
>Express Scripts 4Q profit falls 12 percentPharmacy benefits manager Express Scripts Inc. said Wednesday its profit fell 12 percent in the fourth quarter, mostly on costs related to its proposed acquisition of competitor Medco Health Solutions Inc.
>Factbox: Winners, losers in Obama corporate tax planThe Obama administration on Wednesday proposed a plan to revamp the U.S. corporate tax system, slashing the top tax rate to 28 percent, while eliminating many loopholes that companies rely on to cut their taxes.
Health News - Fox Business
>Employers Grateful for Proposed Tax Breaks, But Still ScaredStruggling business owners are grateful for proposed tax breaks in the president's $450 billion jobs bill but skeptical the relief is enough to lift the gloom.
>Employers Grateful for Proposed Tax Breaks, Still ScaredStruggling business owners are grateful for proposed tax breaks in the president's $450 billion jobs bill but skeptical the relief is enough to lift the gloom.
>Insmed Shares Drop as FDA Halts Study After Rat Test ResultsBiopharmaceutical company, Insmed Incorporated (NYSE:INSM), announced Monday that the U.S. Food and Drug Administration has put the company?s clinical trials for an inhalable antibiotic on hold after reviewing early results from its long-term tests on rats.
>Week Ahead: A Flood Of 2Q EarningsSecond quarter earnings will dominate investors? attention next week, followed closely by housing data.
>Pfizer Drug Raises Heart Attack Risk: StudyNew research shows healthy, middle-aged smokers who take quit-smoking drugs Chantix or Champix have a higher risk of suffering heart attacks.
>Employers Grateful for Proposed Tax Breaks, But Still ScaredStruggling business owners are grateful for proposed tax breaks in the president's $450 billion jobs bill but skeptical the relief is enough to lift the gloom.
>Employers Grateful for Proposed Tax Breaks, Still ScaredStruggling business owners are grateful for proposed tax breaks in the president's $450 billion jobs bill but skeptical the relief is enough to lift the gloom.
>Insmed Shares Drop as FDA Halts Study After Rat Test ResultsBiopharmaceutical company, Insmed Incorporated (NYSE:INSM), announced Monday that the U.S. Food and Drug Administration has put the company?s clinical trials for an inhalable antibiotic on hold after reviewing early results from its long-term tests on rats.
>Week Ahead: A Flood Of 2Q EarningsSecond quarter earnings will dominate investors? attention next week, followed closely by housing data.
>Pfizer Drug Raises Heart Attack Risk: StudyNew research shows healthy, middle-aged smokers who take quit-smoking drugs Chantix or Champix have a higher risk of suffering heart attacks.
Inside Industry - Gen
>Sanofi to Shutter Genzyme's R&D Site in Cambridge, U.K.
>Florida Institute for the Commercialization of Public Research Appoints Entrepreneur Jamie Grooms As New CEO
>EMA Green-Lights Shire's Manufacturing Site in Lexington, MA, for Gaucher Therapy
>NetStar-1 and Whitney, Bradley and Brown, Inc. Merge
>Omeros Wins $1.04M NIDA Grant to Progress NMUR2 Inhibitor Analgesics
>Sanofi to Shutter Genzyme's R&D Site in Cambridge, U.K.
>Florida Institute for the Commercialization of Public Research Appoints Entrepreneur Jamie Grooms As New CEO
>EMA Green-Lights Shire's Manufacturing Site in Lexington, MA, for Gaucher Therapy
>NetStar-1 and Whitney, Bradley and Brown, Inc. Merge
>Omeros Wins $1.04M NIDA Grant to Progress NMUR2 Inhibitor Analgesics
Marketwire - Pharma and Biotech
>Horizon Pharma Secures $60 Million Loan Facility DEERFIELD, IL--(Marketwire - Feb 22, 2012) - Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that it has entered into a loan agreement with a group of lenders to provide $60 million in capital. Horizon used $22.4 million of the loan proceeds to repay the remaining obligations under its loan agreements with Oxford Finance LLC, Silicon Valley Bank and Kreos Capital III (UK) Limited, and expects to use the remainder of the capital to fund the ongoing commercial launch of DUEXIS® in the U....
>Thallion Announces 2011 Year End Results MONTR?L, QU?EC--(Marketwire - Feb. 22, 2012) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced its operational and financial results for the three-month and twelve-month periods ended November 30, 2011.
>Thallion annonce ses r?ltats de fin d'exercice 2011 MONTR?L, QU?EC--(Marketwire - 22 f? 2012) - Thallion Pharmaceutiques Inc. (TSX:TLN) vient d'annoncer aujourd'hui ses r?ltats op?tionnels et financiers pour les p?odes de trois mois et de douze mois ayant pris fin le 30 novembre 2011.
>Medivation Announces Fourth Quarter and Year-End Financial Results Teleconference on February 29, 2012 SAN FRANCISCO, CA--(Marketwire - Feb 22, 2012) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss fourth quarter and year-end financial results and provide a general business update on Wednesday, February 29, 2012 at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended December 31, 2011 will be released after markets close on February 29, 2012.
>Paladin et Somaxon annoncent le d?t d'une pr?ntation de drogue nouvelle pour Silenor(MD) MONTR?L, CANADA ET SAN DIEGO, CALIFORNIE--(Marketwire - 22 f? 2012) - Laboratoires Paladin Inc. (TSX:PLB) et Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) ont annonc?ujourd'hui que Sant?anada avait accept?'examiner une pr?ntation de drogue nouvelle (PDN) d?s?par Paladin pour SilenorMD (dox?ne), un m?cament pour le traitement et le soulagement symptomatique de l'insomnie.
>Horizon Pharma Secures $60 Million Loan Facility DEERFIELD, IL--(Marketwire - Feb 22, 2012) - Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that it has entered into a loan agreement with a group of lenders to provide $60 million in capital. Horizon used $22.4 million of the loan proceeds to repay the remaining obligations under its loan agreements with Oxford Finance LLC, Silicon Valley Bank and Kreos Capital III (UK) Limited, and expects to use the remainder of the capital to fund the ongoing commercial launch of DUEXIS® in the U....
>Thallion Announces 2011 Year End Results MONTR?L, QU?EC--(Marketwire - Feb. 22, 2012) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced its operational and financial results for the three-month and twelve-month periods ended November 30, 2011.
>Thallion annonce ses r?ltats de fin d'exercice 2011 MONTR?L, QU?EC--(Marketwire - 22 f? 2012) - Thallion Pharmaceutiques Inc. (TSX:TLN) vient d'annoncer aujourd'hui ses r?ltats op?tionnels et financiers pour les p?odes de trois mois et de douze mois ayant pris fin le 30 novembre 2011.
>Medivation Announces Fourth Quarter and Year-End Financial Results Teleconference on February 29, 2012 SAN FRANCISCO, CA--(Marketwire - Feb 22, 2012) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss fourth quarter and year-end financial results and provide a general business update on Wednesday, February 29, 2012 at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended December 31, 2011 will be released after markets close on February 29, 2012.
>Paladin et Somaxon annoncent le d?t d'une pr?ntation de drogue nouvelle pour Silenor(MD) MONTR?L, CANADA ET SAN DIEGO, CALIFORNIE--(Marketwire - 22 f? 2012) - Laboratoires Paladin Inc. (TSX:PLB) et Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) ont annonc?ujourd'hui que Sant?anada avait accept?'examiner une pr?ntation de drogue nouvelle (PDN) d?s?par Paladin pour SilenorMD (dox?ne), un m?cament pour le traitement et le soulagement symptomatique de l'insomnie.
MassBio News
>What has made Massachusetts a better place for biotech? Make your nomination by Feb. 24th!This year, in order to recognize companies working to shape Massachusetts as the ideal setting for life sciences companies, the Economic Development Advisory Group (EDAG) at MassBio has established the Leading Edge Award. This award will annually recognize significant contributions made by companies to further Massachusetts as a biotechnology and life sciences hub. Massachusetts is the premier location for the life sciences. Its research hospitals, universities, skilled workforce, and well-...
>MassBio's Peter Abair discusses growth in the cluster with US Building Digest Watch MassBio's Director of Economic Development & Global Affairs, Peter Abair, discuss growth in the Massachusetts Biotech cluster with the US Building Digest in this two-part video! Click here for part 1 Click here for part 2
>MassBio Purchasing Consortium Augments Four Major AgreementsFisher Scientific, Airgas, Linde, & Alert will expand & enhance services for MassBio members MassBio is pleased to announce that four of our primary suppliers will add even more value for our members as we renew agreements in 2012. Fisher Scientific, Airgas, the Linde Group and Alert Scientific will all enhance their offerings. ?MassBio continuously evaluates the needs of members and existing contracts to ensure that we are delivering the best value. We are pleased to have such strong partn...
>Policy Update: FDA Releases Three Draft Guidances on BiosimilarsThe FDA just released three draft guidances on biosimilars, as well as a Fact Sheet and Q and A document. Read BIO's press release: Release of FDA Guidance for Biosimilars Pathway Marks Important Step Forward, Says BIO and visit the FDA website for more information: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm Draft Guidances Guidance for Industry on Biosimilars: Q & As Re...
>STEM Update from the White House: Engage to Excel: Producing One Million Additional College Graduates with STEM DegreesOn Tuesday, February 7 at 3 pm ET the President?s Council of Advisors on Science and Technology (PCAST) released its report entitled ?Engage to Excel: Producing One Million Additional College Graduates with Degrees in Science, Technology, Engineering, and Mathematics.? This report provides a strategy for improving STEM education during the first two years of college that is responsive to both the challenges and the opportunities that this crucial stage in the STEM education pathway presents. ...
>What has made Massachusetts a better place for biotech? Make your nomination by Feb. 24th!This year, in order to recognize companies working to shape Massachusetts as the ideal setting for life sciences companies, the Economic Development Advisory Group (EDAG) at MassBio has established the Leading Edge Award. This award will annually recognize significant contributions made by companies to further Massachusetts as a biotechnology and life sciences hub. Massachusetts is the premier location for the life sciences. Its research hospitals, universities, skilled workforce, and well-...
>MassBio's Peter Abair discusses growth in the cluster with US Building Digest Watch MassBio's Director of Economic Development & Global Affairs, Peter Abair, discuss growth in the Massachusetts Biotech cluster with the US Building Digest in this two-part video! Click here for part 1 Click here for part 2
>MassBio Purchasing Consortium Augments Four Major AgreementsFisher Scientific, Airgas, Linde, & Alert will expand & enhance services for MassBio members MassBio is pleased to announce that four of our primary suppliers will add even more value for our members as we renew agreements in 2012. Fisher Scientific, Airgas, the Linde Group and Alert Scientific will all enhance their offerings. ?MassBio continuously evaluates the needs of members and existing contracts to ensure that we are delivering the best value. We are pleased to have such strong partn...
>Policy Update: FDA Releases Three Draft Guidances on BiosimilarsThe FDA just released three draft guidances on biosimilars, as well as a Fact Sheet and Q and A document. Read BIO's press release: Release of FDA Guidance for Biosimilars Pathway Marks Important Step Forward, Says BIO and visit the FDA website for more information: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm Draft Guidances Guidance for Industry on Biosimilars: Q & As Re...
>STEM Update from the White House: Engage to Excel: Producing One Million Additional College Graduates with STEM DegreesOn Tuesday, February 7 at 3 pm ET the President?s Council of Advisors on Science and Technology (PCAST) released its report entitled ?Engage to Excel: Producing One Million Additional College Graduates with Degrees in Science, Technology, Engineering, and Mathematics.? This report provides a strategy for improving STEM education during the first two years of college that is responsive to both the challenges and the opportunities that this crucial stage in the STEM education pathway presents. ...
Medical Pharma - PR Newswire
>Muhammad Ali Salutes Medical CommunityPHOENIX, Feb. 22, 2012 /PRNewswire/ -- Surrounded by medical heavyweights, Muhammad Ali continued the fight today by honoring 50 top surgeons and physicians at Barrow Neurological Institute in Phoenix, Arizona. Barrow at St. Joseph's Hospital and Medical Center is home of the...
>The Icla da Silva Foundation To Host a Free Informational BreakfastWhat You Should Know About Storing or Donating Your Baby's Cord Blood NEW YORK, Feb. 22, 2012 /PRNewswire-USNewswire/ -- The Icla da Silva Foundation is hosting a free informational breakfast in an effort to increase awareness of available cord blood storage and donation...
>Accelitech to Open the First CyberKnife Cancer Center Within the City of ChicagoCHICAGO, Feb. 22, 2012 /PRNewswire/ -- Accelitech LLC, a leading developer of stereotactic radiosurgery and cancer treatment programs, is pleased to announce its newest CyberKnife cancer center, which will begin treating patients in Chicago in the summer of 2012. Developed...
>Sequenom, Inc. Files Motion for Preliminary Injunction Against Aria DiagnosticsSAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has filed a motion for preliminary injunction against Aria Diagnostics ("Aria") to stop Aria from making, using,...
>ACGME Announces Plan to Transform How Medical Residency Programs Will Educate Future Physicians for a Changing Health Care SystemCHICAGO, Feb. 22, 2012 /PRNewswire-USNewswire/ -- The Accreditation Council for Graduate Medical Education (ACGME) today announced major changes in how the nation's medical residency programs will be accredited in the years ahead, putting in place an outcomes-based evaluation...
>Muhammad Ali Salutes Medical CommunityPHOENIX, Feb. 22, 2012 /PRNewswire/ -- Surrounded by medical heavyweights, Muhammad Ali continued the fight today by honoring 50 top surgeons and physicians at Barrow Neurological Institute in Phoenix, Arizona. Barrow at St. Joseph's Hospital and Medical Center is home of the...
>The Icla da Silva Foundation To Host a Free Informational BreakfastWhat You Should Know About Storing or Donating Your Baby's Cord Blood NEW YORK, Feb. 22, 2012 /PRNewswire-USNewswire/ -- The Icla da Silva Foundation is hosting a free informational breakfast in an effort to increase awareness of available cord blood storage and donation...
>Accelitech to Open the First CyberKnife Cancer Center Within the City of ChicagoCHICAGO, Feb. 22, 2012 /PRNewswire/ -- Accelitech LLC, a leading developer of stereotactic radiosurgery and cancer treatment programs, is pleased to announce its newest CyberKnife cancer center, which will begin treating patients in Chicago in the summer of 2012. Developed...
>Sequenom, Inc. Files Motion for Preliminary Injunction Against Aria DiagnosticsSAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has filed a motion for preliminary injunction against Aria Diagnostics ("Aria") to stop Aria from making, using,...
>ACGME Announces Plan to Transform How Medical Residency Programs Will Educate Future Physicians for a Changing Health Care SystemCHICAGO, Feb. 22, 2012 /PRNewswire-USNewswire/ -- The Accreditation Council for Graduate Medical Education (ACGME) today announced major changes in how the nation's medical residency programs will be accredited in the years ahead, putting in place an outcomes-based evaluation...
National Center for Biotechnology Information
>GEO Series ReleasesNotifications of functional genomic studies released by the Gene Expression Omnibus (GEO) database.
>ClinVar News and AnnouncementsBrief Announcements highlighting recent changes and enhancements to ClinVar database.
>Behind The Headlines - Health News from NHS ChoicesBehind the Headlines is a constantly updated health news across a range of subjects. It provides an unbiased and evidence-based analysis of health stories that make the news. Published by UK NHS Choices.
>PubMed Health Featured ReviewsPubMed Health featured clinical effectiveness reviews
>SRA NewsBrief annoucements for new features and pipeline changes to the Sequence Read Archive.
>GEO Series ReleasesNotifications of functional genomic studies released by the Gene Expression Omnibus (GEO) database.
>ClinVar News and AnnouncementsBrief Announcements highlighting recent changes and enhancements to ClinVar database.
>Behind The Headlines - Health News from NHS ChoicesBehind the Headlines is a constantly updated health news across a range of subjects. It provides an unbiased and evidence-based analysis of health stories that make the news. Published by UK NHS Choices.
>PubMed Health Featured ReviewsPubMed Health featured clinical effectiveness reviews
>SRA NewsBrief annoucements for new features and pipeline changes to the Sequence Read Archive.
Nature Biotechnology
>OpenVigil?free eyeballs on AERS pharmacovigilance data
>The blinded buyer
>Planning for the exit
>PRIDE Inspector: a tool to visualize and validate MS proteomics data
>2011?Big biotechs gorge on debt
>OpenVigil?free eyeballs on AERS pharmacovigilance data
>The blinded buyer
>Planning for the exit
>PRIDE Inspector: a tool to visualize and validate MS proteomics data
>2011?Big biotechs gorge on debt
New York Times- Biotechnology
>Cancer Center, in Suit, Claims Ex-Official Took ResearchThe president of Memorial Sloan-Kettering Cancer Center, Dr. Craig B. Thompson, is in a billion-dollar dispute with his former workplace over accusations that he walked away with research.
>Life Sciences Development Rebounds in Central New JerseyWith its concentration of pharmaceutical giants and academic powerhouses, the region could be a major center for life sciences businesses, developers say.
>Amgen and Watson to Work Together on Generic DrugsThe two companies will develop and sell cheaper versions of several biologic cancer drugs.
>A Genome DelugeDNA sequencing is becoming faster and cheaper, outrunning the ability to store, transmit and analyze the data; this could delay the day when DNA sequencing is routinely used in medicine. Photo
>Drew Endy: Better Computing for the Things We Care About MostFrom scheduling conference rooms to rooting out incipient tumors, computers that can go to the information that we care greatly about
>Cancer Center, in Suit, Claims Ex-Official Took ResearchThe president of Memorial Sloan-Kettering Cancer Center, Dr. Craig B. Thompson, is in a billion-dollar dispute with his former workplace over accusations that he walked away with research.
>Life Sciences Development Rebounds in Central New JerseyWith its concentration of pharmaceutical giants and academic powerhouses, the region could be a major center for life sciences businesses, developers say.
>Amgen and Watson to Work Together on Generic DrugsThe two companies will develop and sell cheaper versions of several biologic cancer drugs.
>A Genome DelugeDNA sequencing is becoming faster and cheaper, outrunning the ability to store, transmit and analyze the data; this could delay the day when DNA sequencing is routinely used in medicine. Photo
>Drew Endy: Better Computing for the Things We Care About MostFrom scheduling conference rooms to rooting out incipient tumors, computers that can go to the information that we care greatly about
New York Times- Pharmaceuticals
>Qnexa Weight-Loss Drug Wins Advisory Panel’s SupportA committee recommended that the Food and Drug Administration approve what could become the first new prescription drug to treat obesity in 13 years.
>Qnexa Weight-Loss Drug Is Approved by Advisory PanelA committee recommended that the Food and Drug Administration approve what could become the first new prescription drug to treat obesity in 13 years.
>F.D.A. Approves Imports Amid Shortage of 2 Cancer DrugsDoxil, used for ovarian cancer, and methotrexate, for a common form of childhood leukemia, are among scores of drugs whose shortfall is threatening lives in the United States.
>Finally, Outrage in China Against Bear FarmingThe practice of bear farming -- and the milking of the bears for their allegedly medicinal bile --- is gruesome enough that hundreds of thousands of Chinese have attacked a pharmaceutical company with online complaints over the firm's plans to triple the size of its bear farms with a public offering of shares on the Shenzhen stock exchange. Still, the practice continues.
>A Frightening Shortage of Vital DrugsThe severe shortage of a drug used to treat childhood leukemia highlights why Congress must pass legislation giving the F.D.A. more power to head off such a crisis.
>Qnexa Weight-Loss Drug Wins Advisory Panel’s SupportA committee recommended that the Food and Drug Administration approve what could become the first new prescription drug to treat obesity in 13 years.
>Qnexa Weight-Loss Drug Is Approved by Advisory PanelA committee recommended that the Food and Drug Administration approve what could become the first new prescription drug to treat obesity in 13 years.
>F.D.A. Approves Imports Amid Shortage of 2 Cancer DrugsDoxil, used for ovarian cancer, and methotrexate, for a common form of childhood leukemia, are among scores of drugs whose shortfall is threatening lives in the United States.
>Finally, Outrage in China Against Bear FarmingThe practice of bear farming -- and the milking of the bears for their allegedly medicinal bile --- is gruesome enough that hundreds of thousands of Chinese have attacked a pharmaceutical company with online complaints over the firm's plans to triple the size of its bear farms with a public offering of shares on the Shenzhen stock exchange. Still, the practice continues.
>A Frightening Shortage of Vital DrugsThe severe shortage of a drug used to treat childhood leukemia highlights why Congress must pass legislation giving the F.D.A. more power to head off such a crisis.
OnBioVC
>OnBioVC 4Q11 & 2011 | Trend Analysis Now AvailableThe 4Q11 & 2011 OnBioVC Trend Analysis study is available for download [HERE]. OnBioVC the industry leader in organizing and reporting life science private venture financings, today announced the release of its 2011 Trend Analysis. The 4Q11 OnBioVC Trend Analysis tracked, in aggregate, 93 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,662.8M, compared to [...]
>Arteaus Therapeutics, LLC: Series A $18MArteaus Therapeutics (Cambridge, MA) a development-stage biopharmaceutical company focused on antibody treatment for the prevention of migraine headache, closed a $18M Series A financing. Participants include Atlas Venture and OrbiMed.
>100Plus, Inc.: Series A $1.3M100Plus (San Francisco, CA) a development-stage personalized health applications company focused on behavior modifications, closed a $1.3M Series A financing. Participants include Founders Fund, Greylock Partners and Band of Angels.
>EndoEvolution, LLC: Series B $3.3MEndoEvolution (North Chelmsford, MA) a development-stage medical device company focused on minimally invasive surgery and automated suturing devices, closed a $3.3M Series B financing. Participants include Spring Bay Companies.
>Cleave Biosciences, Inc.: Series A $44MCleave Biosciences (Burlingame, CA) a preclinical-stage pharmaceutical company focused on small molecules for oncology, closed a $42M Series A financing. Participants include US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors and Astellas Venture Management.
>OnBioVC 4Q11 & 2011 | Trend Analysis Now AvailableThe 4Q11 & 2011 OnBioVC Trend Analysis study is available for download [HERE]. OnBioVC the industry leader in organizing and reporting life science private venture financings, today announced the release of its 2011 Trend Analysis. The 4Q11 OnBioVC Trend Analysis tracked, in aggregate, 93 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,662.8M, compared to [...]
>Arteaus Therapeutics, LLC: Series A $18MArteaus Therapeutics (Cambridge, MA) a development-stage biopharmaceutical company focused on antibody treatment for the prevention of migraine headache, closed a $18M Series A financing. Participants include Atlas Venture and OrbiMed.
>100Plus, Inc.: Series A $1.3M100Plus (San Francisco, CA) a development-stage personalized health applications company focused on behavior modifications, closed a $1.3M Series A financing. Participants include Founders Fund, Greylock Partners and Band of Angels.
>EndoEvolution, LLC: Series B $3.3MEndoEvolution (North Chelmsford, MA) a development-stage medical device company focused on minimally invasive surgery and automated suturing devices, closed a $3.3M Series B financing. Participants include Spring Bay Companies.
>Cleave Biosciences, Inc.: Series A $44MCleave Biosciences (Burlingame, CA) a preclinical-stage pharmaceutical company focused on small molecules for oncology, closed a $42M Series A financing. Participants include US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors and Astellas Venture Management.
Outsourcing-Pharma
>An experienced CMO is key to successful biologics development says Cobra BiologicsDetailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.
>Parexel discusses transdermal drug delivery techsElectroporation is the wave of the future for transdermal drug delivery, according to Parexel?s Ravi Harapanhalli.
>Sponsors and CROs differ on perception of service quality, says the Avoca GroupSponsor and CRO perceptions of the quality of outsourced service provision differ markedly according to a study by consulting and survey research organisation, the Avoca Group.
>Recipharm CEO talks CMO sector recovery and Asian plansThe global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.
>Covance adding mass spec for biosimilarsCovance is adding mass spectrometry and other capabilities to meet growing demand for biosimilar comparability services.
>An experienced CMO is key to successful biologics development says Cobra BiologicsDetailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.
>Parexel discusses transdermal drug delivery techsElectroporation is the wave of the future for transdermal drug delivery, according to Parexel?s Ravi Harapanhalli.
>Sponsors and CROs differ on perception of service quality, says the Avoca GroupSponsor and CRO perceptions of the quality of outsourced service provision differ markedly according to a study by consulting and survey research organisation, the Avoca Group.
>Recipharm CEO talks CMO sector recovery and Asian plansThe global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.
>Covance adding mass spec for biosimilarsCovance is adding mass spectrometry and other capabilities to meet growing demand for biosimilar comparability services.
Pharma News - Business Wire
>Dendreon Announces New Time for Fourth Quarter and Year-End Financial Results Conference Call and Webcast Presentations at Upcoming ConferencesSEATTLE--(BUSINESS WIRE)--February 22, 2012 ? Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 27, 2012, at 9:00 a.m. ET to review fourth quarter and year-end financial results. This conference call was previously scheduled at 4:30 p.m. ET on the same date. Access to the discussion may be obtained as follows: Time: 9:00 a.m. ET / 6:00 a.m. PT Date: February 27, 2012 Dial-in: 1-877-548-9590 (domestic) or +1-720-545-00...
>Catalyst Health Solutions, Inc. to Present at the Citi 2012 Global Health Care ConferenceROCKVILLE, Md.--(BUSINESS WIRE)--Catalyst Health Solutions, Inc. (NASDAQ: CHSI) announced today that David T. Blair, Chairman and Chief Executive Officer, is scheduled to present at the Citi 2012 Global Health Care Conference on Tuesday, February 28, 2012, at approximately 4:00 p.m. ET in New York. The presentation will be available on Catalyst Health Solutions? web site at www.chsi.com. About Catalyst Health Solutions, Inc. (www.chsi.com): Catalyst Health Solutions, Inc., the fastest growing...
>Paladin and Somaxon Announce Filing of New Drug Submission for Silenor®MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Paladin Labs and Somaxon Pharmaceuticals announced that Paladin has filed a New Drug Submission that has been accepted for review by Health Canada for Silenor® (doxepin)
>INSERTING and REPLACING Human Genome Sciences to Sponsor Conference Call to Discuss Fourth-Quarter and Full-Year 2011 Financial ResultsROCKVILLE, Md.--(BUSINESS WIRE)--Insert after first paragraph: The conference call will be hosted by senior management and will be held on Monday, February 27, 2012 at 4:30 pm Eastern time. The corrected release reads: HUMAN GENOME SCIENCES TO SPONSOR CONFERENCE CALL TO DISCUSS FOURTH-QUARTER AND FULL-YEAR 2011 FINANCIAL RESULTS Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that it will sponsor a conference call to discuss its financial results for the fourth-quarter and full-yea...
>Oxygen Biotherapeutics Announces Third Quarter FY2012 Financial Results Conference Call and WebcastMORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) today announced that the Company plans to report third quarter fiscal year 2012 financial results on Form 10-Q on Thursday, March 15, 2012. Oxygen?s President & Chief Financial Officer, Michael Jebsen, will host a conference call and live webcast to discuss the results on Friday, March 16, 2012, at 11 a.m. EDT. To access the live teleconference, dial 866-510-0710 (U.S. and Canada) or 617-597-5378 (international.) ...
>Dendreon Announces New Time for Fourth Quarter and Year-End Financial Results Conference Call and Webcast Presentations at Upcoming ConferencesSEATTLE--(BUSINESS WIRE)--February 22, 2012 ? Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 27, 2012, at 9:00 a.m. ET to review fourth quarter and year-end financial results. This conference call was previously scheduled at 4:30 p.m. ET on the same date. Access to the discussion may be obtained as follows: Time: 9:00 a.m. ET / 6:00 a.m. PT Date: February 27, 2012 Dial-in: 1-877-548-9590 (domestic) or +1-720-545-00...
>Catalyst Health Solutions, Inc. to Present at the Citi 2012 Global Health Care ConferenceROCKVILLE, Md.--(BUSINESS WIRE)--Catalyst Health Solutions, Inc. (NASDAQ: CHSI) announced today that David T. Blair, Chairman and Chief Executive Officer, is scheduled to present at the Citi 2012 Global Health Care Conference on Tuesday, February 28, 2012, at approximately 4:00 p.m. ET in New York. The presentation will be available on Catalyst Health Solutions? web site at www.chsi.com. About Catalyst Health Solutions, Inc. (www.chsi.com): Catalyst Health Solutions, Inc., the fastest growing...
>Paladin and Somaxon Announce Filing of New Drug Submission for Silenor®MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Paladin Labs and Somaxon Pharmaceuticals announced that Paladin has filed a New Drug Submission that has been accepted for review by Health Canada for Silenor® (doxepin)
>INSERTING and REPLACING Human Genome Sciences to Sponsor Conference Call to Discuss Fourth-Quarter and Full-Year 2011 Financial ResultsROCKVILLE, Md.--(BUSINESS WIRE)--Insert after first paragraph: The conference call will be hosted by senior management and will be held on Monday, February 27, 2012 at 4:30 pm Eastern time. The corrected release reads: HUMAN GENOME SCIENCES TO SPONSOR CONFERENCE CALL TO DISCUSS FOURTH-QUARTER AND FULL-YEAR 2011 FINANCIAL RESULTS Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that it will sponsor a conference call to discuss its financial results for the fourth-quarter and full-yea...
>Oxygen Biotherapeutics Announces Third Quarter FY2012 Financial Results Conference Call and WebcastMORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) today announced that the Company plans to report third quarter fiscal year 2012 financial results on Form 10-Q on Thursday, March 15, 2012. Oxygen?s President & Chief Financial Officer, Michael Jebsen, will host a conference call and live webcast to discuss the results on Friday, March 16, 2012, at 11 a.m. EDT. To access the live teleconference, dial 866-510-0710 (U.S. and Canada) or 617-597-5378 (international.) ...
Pharma News - PharmiWeb
>Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of iceMachine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of icePR Newswi...Organ Recovery Systems
>Dr. Ali Gheissari Selected For Patients' Choice Award 2011Dr. Ali Gheissari Selected For Patients' Choice Award 2011PR NewswireLOS ANGELES, Feb. 22, 2012Dr. Ali Gheissari of Los An...AMERICAN REGISTRY LLC
>Dr. Michael Keller Selected For Patients' Choice Award 2011Dr. Michael Keller Selected For Patients' Choice Award 2011PR NewswireDENVER, Feb. 22, 2012 Dr. Michael Keller of Denver, ...AMERICAN REGISTRY LLC
>New Center Helps Cancer Patients Preserve FertilityNew Center Helps Cancer Patients Preserve FertilityPR NewswireFAIRFAX, Va., Feb. 22, 2012FAIRFAX, Va., Feb. 22, 2012 /PRNewswir...LEONARD COMMUNICATIONS
>Bruker Announces Senior Operations Management AppointmentBruker Announces Senior Operations Management Appointment Bruker Corporation has announced the appointment of Mr. Stephan West...Bruker Corporation
>Machine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of iceMachine Preservation Significantly Improves Kidney Transplant Survival Over 3 Years Compared to Traditional box of icePR Newswi...Organ Recovery Systems
>Dr. Ali Gheissari Selected For Patients' Choice Award 2011Dr. Ali Gheissari Selected For Patients' Choice Award 2011PR NewswireLOS ANGELES, Feb. 22, 2012Dr. Ali Gheissari of Los An...AMERICAN REGISTRY LLC
>Dr. Michael Keller Selected For Patients' Choice Award 2011Dr. Michael Keller Selected For Patients' Choice Award 2011PR NewswireDENVER, Feb. 22, 2012 Dr. Michael Keller of Denver, ...AMERICAN REGISTRY LLC
>New Center Helps Cancer Patients Preserve FertilityNew Center Helps Cancer Patients Preserve FertilityPR NewswireFAIRFAX, Va., Feb. 22, 2012FAIRFAX, Va., Feb. 22, 2012 /PRNewswir...LEONARD COMMUNICATIONS
>Bruker Announces Senior Operations Management AppointmentBruker Announces Senior Operations Management Appointment Bruker Corporation has announced the appointment of Mr. Stephan West...Bruker Corporation
Pharma News - PR Newswire
>FDA Advisory Committee Recommends Approval of Qnexa®MOUNTAIN VIEW, Calif., Feb. 22, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in...
>Endo Pharmaceuticals to Present at Cowen & Co. 32nd Annual Health Care ConferenceCHADDS FORD, Pa., Feb. 22, 2012 /PRNewswire/ -- Endo Pharmaceuticals Holdings (Nasdaq: ENDP) today announced that Julie McHugh, chief operating officer, will present a corporate overview at the Cowen & Co. 32nd Annual Heath Care Conference on Wednesday, March 7, 2012 at...
>Onyx Pharmaceuticals Completes Enrollment in ASPIRE Phase 3 Carfilzomib Combination Trial for the Potential Treatment of Relapsed Multiple MyelomaSOUTH SAN FRANCISCO, Calif., Feb. 22, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide...
>American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible ParticlesSHIRLEY, N.Y., Feb. 22, 2012 /PRNewswire/ -- American Regent is conducting a nationwide voluntary recall to the Retail/Hospital level of the following product: Phenylephrine HCl Injection, USP, 1% (10mg/mL), 5 mL VialNDC # 0517-0405-25, Lot # 0693, Exp Date: October,...
>Watson to Present at the 2012 RBC Capital Markets' Healthcare ConferencePARSIPPANY, N.J., Feb. 22, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business...
>FDA Advisory Committee Recommends Approval of Qnexa®MOUNTAIN VIEW, Calif., Feb. 22, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in...
>Endo Pharmaceuticals to Present at Cowen & Co. 32nd Annual Health Care ConferenceCHADDS FORD, Pa., Feb. 22, 2012 /PRNewswire/ -- Endo Pharmaceuticals Holdings (Nasdaq: ENDP) today announced that Julie McHugh, chief operating officer, will present a corporate overview at the Cowen & Co. 32nd Annual Heath Care Conference on Wednesday, March 7, 2012 at...
>Onyx Pharmaceuticals Completes Enrollment in ASPIRE Phase 3 Carfilzomib Combination Trial for the Potential Treatment of Relapsed Multiple MyelomaSOUTH SAN FRANCISCO, Calif., Feb. 22, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide...
>American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible ParticlesSHIRLEY, N.Y., Feb. 22, 2012 /PRNewswire/ -- American Regent is conducting a nationwide voluntary recall to the Retail/Hospital level of the following product: Phenylephrine HCl Injection, USP, 1% (10mg/mL), 5 mL VialNDC # 0517-0405-25, Lot # 0693, Exp Date: October,...
>Watson to Present at the 2012 RBC Capital Markets' Healthcare ConferencePARSIPPANY, N.J., Feb. 22, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business...
Pharmaceutical - Moreover
>: Pharmaceuticals look to cure pipeline concernsPharmaceutical companies are considered to be one of the more defensive sectors, with high margins, significant non-cyclical cashflows and relatively low levels of leverage all helping contribute to good performance in
>Drug firms sign up to new tropical disease fightKey players in the pharmaceutical industry pledged on Monday to donate 14 billion drug treatments as part of a new, global push to eradicate tropical diseases
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are NoCannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to share new photographs from this cancer patient with severe squamous cell carcinoma. These pictures clearly show that this patient
>Micro Labs attracts private equity and pharma interest: VCCircleAnother high value deal in India?s pharmaceutical sector may be in the pipeline, as Bangalore?s Micro Labs attracts the interest of major drug companies Teva and Pfizer, as well as private equity houses, people with knowledge
>Novartis net dips by 5.3% to Rs.38 crore in Q3worked out to Rs.11.99 as against Rs.12.67 in the last period. The company's pharmaceutical sales increased to Rs.142.20 crore from Rs.124.9 crore, registering a growth of 13.9 per cent during the quarter under review. Its generic division sales increased
>: Pharmaceuticals look to cure pipeline concernsPharmaceutical companies are considered to be one of the more defensive sectors, with high margins, significant non-cyclical cashflows and relatively low levels of leverage all helping contribute to good performance in
>Drug firms sign up to new tropical disease fightKey players in the pharmaceutical industry pledged on Monday to donate 14 billion drug treatments as part of a new, global push to eradicate tropical diseases
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are NoCannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to share new photographs from this cancer patient with severe squamous cell carcinoma. These pictures clearly show that this patient
>Micro Labs attracts private equity and pharma interest: VCCircleAnother high value deal in India?s pharmaceutical sector may be in the pipeline, as Bangalore?s Micro Labs attracts the interest of major drug companies Teva and Pfizer, as well as private equity houses, people with knowledge
>Novartis net dips by 5.3% to Rs.38 crore in Q3worked out to Rs.11.99 as against Rs.12.67 in the last period. The company's pharmaceutical sales increased to Rs.142.20 crore from Rs.124.9 crore, registering a growth of 13.9 per cent during the quarter under review. Its generic division sales increased
PR Leap - Biotech
>Abcam Biochemicals is launched; the new name for Ascent Scientific productsAbcam Biochemicals is the new name for the Ascent Scientific range of exceptional quality, high performance biochemicals.
>AL-TAR Services, Inc. Adds Thermo-Scientific Product Line to its Online Lab Equipment Store AL-TAR Services, Inc. announces new sales channel partnership with Thermo-Scientific laboratory equipment.
>Ascent Scientific Launch Novel Dynamin Inhibitor Dyngo-4a™ with Children's Medical Research Institute and University of NewcastleAscent Scientific together with Children's Medical Research Institute and The University of Newcastle today announced that they have entered into a license, supply and distribution agreement for the highly potent dynamin inhibitor Dyngo-4a™. This novel compound joins a range of dynamin inhibitors that can be used for investigating cellular processes such as endocytosis. The agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.
>AL-TAR Services, Inc. Names Robert Nugent Director of Business Development AL-TAR Services, Inc. welcomes Robert Nugent as new Director of Business Development for AL-TAR's team of laboratory equipment calibration and repair experts.
>Ascent Scientific licenses novel clathrin inhibitors from Freie Universität Berlin, University of Newcastle and Children's Medical Research InstituteAscent Scientific, together with Freie Universität Berlin, The University of Newcastle and Children's Medical Research Institute today announced that they have entered into an exclusive licence, supply and distribution agreement for the clathrin inhibitors Pitstop 1™ and Pitstop 2™ for research. These novel compounds are the first rationally designed inhibitors of clathrin, and represent important tools for investigating essential cellular processes such as endocytosis.
>Abcam Biochemicals is launched; the new name for Ascent Scientific productsAbcam Biochemicals is the new name for the Ascent Scientific range of exceptional quality, high performance biochemicals.
>AL-TAR Services, Inc. Adds Thermo-Scientific Product Line to its Online Lab Equipment Store AL-TAR Services, Inc. announces new sales channel partnership with Thermo-Scientific laboratory equipment.
>Ascent Scientific Launch Novel Dynamin Inhibitor Dyngo-4a™ with Children's Medical Research Institute and University of NewcastleAscent Scientific together with Children's Medical Research Institute and The University of Newcastle today announced that they have entered into a license, supply and distribution agreement for the highly potent dynamin inhibitor Dyngo-4a™. This novel compound joins a range of dynamin inhibitors that can be used for investigating cellular processes such as endocytosis. The agreement was facilitated by Bio-Link Australia, a life sciences commercialisation company.
>AL-TAR Services, Inc. Names Robert Nugent Director of Business Development AL-TAR Services, Inc. welcomes Robert Nugent as new Director of Business Development for AL-TAR's team of laboratory equipment calibration and repair experts.
>Ascent Scientific licenses novel clathrin inhibitors from Freie Universität Berlin, University of Newcastle and Children's Medical Research InstituteAscent Scientific, together with Freie Universität Berlin, The University of Newcastle and Children's Medical Research Institute today announced that they have entered into an exclusive licence, supply and distribution agreement for the clathrin inhibitors Pitstop 1™ and Pitstop 2™ for research. These novel compounds are the first rationally designed inhibitors of clathrin, and represent important tools for investigating essential cellular processes such as endocytosis.
PRWeb - Biotechnology
>Bayer Initiates Global ?Bee Care Program? to Further Promote Bee... ?Bayer Bee Care Centers? to open in Europe and the USA(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9218703.htm
>MediVet-America Partners With Butler Schein Animal Health to... Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company.(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9218989.htm
>Bayer CropScience Hosts Sustainability In Agriculture: A Bayer... Event Presented In Partnership With College Of Agriculture And Life Sciences And Poole College Of Management At North Carolina State University(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/Bayer/CropScience/prweb9216297.htm
>Life Extension For All: Global Future Congress Announces ?Avatar? World?s Leading Scientists Meet in Moscow to Announce Life Extension Project for Civilians; U.S. Launches Military Version(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9216278.htm
>Global Tissue Engineering Market Review Recently Published at... New market research report ?Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview? developed by Industry Experts has been recently published by Market Publishers...(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9218109.htm
>Bayer Initiates Global ?Bee Care Program? to Further Promote Bee... ?Bayer Bee Care Centers? to open in Europe and the USA(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9218703.htm
>MediVet-America Partners With Butler Schein Animal Health to... Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company.(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9218989.htm
>Bayer CropScience Hosts Sustainability In Agriculture: A Bayer... Event Presented In Partnership With College Of Agriculture And Life Sciences And Poole College Of Management At North Carolina State University(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/Bayer/CropScience/prweb9216297.htm
>Life Extension For All: Global Future Congress Announces ?Avatar? World?s Leading Scientists Meet in Moscow to Announce Life Extension Project for Civilians; U.S. Launches Military Version(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9216278.htm
>Global Tissue Engineering Market Review Recently Published at... New market research report ?Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview? developed by Industry Experts has been recently published by Market Publishers...(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9218109.htm
PRWeb - Pharmaceuticals
>PCMA: Mail-Service Pharmacies Will Save Pennsylvania Consumers and... Mail-service pharmacies will save Pennsylvania consumers, employers, unions, the state government, and other commercially-insured payers $2 billion in prescription drug costs over the next ten years,...(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9218996.htm
>PCMA: Mail-Service Pharmacies Will Save Missouri Consumers and Payers... Mail-service pharmacies will save Missouri consumers, employers, unions, the state government, and other commercially-insured payers $914 million in prescription drug costs over the next ten years,...(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9219073.htm
>Precision Solutions Group Expands Service Offerings to all IBM i... Unique support model will address a company?s entire business software environment(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9212622.htm
>Improve Population Health Management and Outcomes with the New... HealthyCircles launches a Spanish version of its online Care Management and Coordination Platform, helping health care professionals improve population health management and outcomes.(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/Spanish/HealthyCircles/prweb9201919.htm
>Improve Business Performance and CyberSecurity: Free White Paper... Download the paper today at http://www.businesscybersecurity.com.(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9217013.htm
>PCMA: Mail-Service Pharmacies Will Save Pennsylvania Consumers and... Mail-service pharmacies will save Pennsylvania consumers, employers, unions, the state government, and other commercially-insured payers $2 billion in prescription drug costs over the next ten years,...(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9218996.htm
>PCMA: Mail-Service Pharmacies Will Save Missouri Consumers and Payers... Mail-service pharmacies will save Missouri consumers, employers, unions, the state government, and other commercially-insured payers $914 million in prescription drug costs over the next ten years,...(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9219073.htm
>Precision Solutions Group Expands Service Offerings to all IBM i... Unique support model will address a company?s entire business software environment(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9212622.htm
>Improve Population Health Management and Outcomes with the New... HealthyCircles launches a Spanish version of its online Care Management and Coordination Platform, helping health care professionals improve population health management and outcomes.(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/Spanish/HealthyCircles/prweb9201919.htm
>Improve Business Performance and CyberSecurity: Free White Paper... Download the paper today at http://www.businesscybersecurity.com.(PRWeb February 22, 2012)Read the full story at http://www.prweb.com/releases/2012/2/prweb9217013.htm
Scientific American
>New Family of Limbless Amphibians Discovered in IndiaFrom Nature magazine. [More]
>Co-opulation: Sometimes It Takes More Than 2 to Tango [Slide Show]Dawn Higginson thought it was strange when she learned that some diving beetles produce sperm that fuse together at the head like Siamese twins. But when the postdoctoral researcher from the University of Arizona began asking why such conjugate gametes form, things only got even stranger. The sperm of the diving beetle, which gets its name from its ability to swim underwater, occur in many shapes and forms. Whereas a few species make standard tadpole-shaped swimmers, others generate sperm tha...
>Dual Interpretations: Milky Way's Outer Fringe of Stars Sparks DisagreementIt's well known that the Milky Way is a spiral galaxy, a swirl of stars in an extended, many-armed disk . But the structure of the galaxy is far from two-dimensional. Above and below those familiar spiral arms is a lesser-known feature, a spherical swarm of stars that makes up a halo around the disk. [More]
>Fossilized, 'Pompeii' Forest Discovered Under AshAbout 300 million years ago, volcanic ash buried a tropical forest located in what is now Inner Mongolia, much like it did the ancient Roman city of Pompeii. [More]
>Co-oppulation: Sometimes It Takes More Than 2 to Tango [Slide Show]Dawn Higginson thought it was strange when she learned that some diving beetles produce sperm that fuse together at the head like Siamese twins. But when the postdoctoral researcher from the University of Arizona began asking why such conjugate gametes form, things only got even stranger. The sperm of the diving beetle, which gets its name from its ability to swim underwater, occur in many shapes and forms. Whereas a few species make standard tadpole-shaped swimmers, others generate sperm tha...
>New Family of Limbless Amphibians Discovered in IndiaFrom Nature magazine. [More]
>Co-opulation: Sometimes It Takes More Than 2 to Tango [Slide Show]Dawn Higginson thought it was strange when she learned that some diving beetles produce sperm that fuse together at the head like Siamese twins. But when the postdoctoral researcher from the University of Arizona began asking why such conjugate gametes form, things only got even stranger. The sperm of the diving beetle, which gets its name from its ability to swim underwater, occur in many shapes and forms. Whereas a few species make standard tadpole-shaped swimmers, others generate sperm tha...
>Dual Interpretations: Milky Way's Outer Fringe of Stars Sparks DisagreementIt's well known that the Milky Way is a spiral galaxy, a swirl of stars in an extended, many-armed disk . But the structure of the galaxy is far from two-dimensional. Above and below those familiar spiral arms is a lesser-known feature, a spherical swarm of stars that makes up a halo around the disk. [More]
>Fossilized, 'Pompeii' Forest Discovered Under AshAbout 300 million years ago, volcanic ash buried a tropical forest located in what is now Inner Mongolia, much like it did the ancient Roman city of Pompeii. [More]
>Co-oppulation: Sometimes It Takes More Than 2 to Tango [Slide Show]Dawn Higginson thought it was strange when she learned that some diving beetles produce sperm that fuse together at the head like Siamese twins. But when the postdoctoral researcher from the University of Arizona began asking why such conjugate gametes form, things only got even stranger. The sperm of the diving beetle, which gets its name from its ability to swim underwater, occur in many shapes and forms. Whereas a few species make standard tadpole-shaped swimmers, others generate sperm tha...
Sports - ESPN Basketball
>Marquette rolls Rutgers to keep up in Big East Jae Crowder scored 27 points and Darius Johnson-Odom added 21 to lead No. 10 Marquette to an 82-65 victory over Rutgers on Wednesday night.
>Wichita St. shreds Illinois St. to clinch MVC title No. 19 Wichita St. 68, Illinois St. 55
>No. 5 KU halts late A&M run as Taylor steps up Elijah Johnson scored 21 points and Tyshawn Taylor made key plays down the stretch to help No. 4 Kansas fight off a late run by Texas A&M for a 66-58 victory Wednesday night.
>Spartans fend off Gophers to stay atop Big Ten Keith Appling and Brandon Wood both scored 13 points to key No. 6 Michigan State's 66-61 victory over Minnesota on Wednesday night, helping the Spartans keep their hold on first place in the Big Ten.
>Moore leads No. 22 Temple past La Salle in OT Ramone Moore scored five of his 18 points in overtime to help No. 22 Temple beat La Salle 80-79 on Wednesday night, the Owls' 11th straight win.
>Marquette rolls Rutgers to keep up in Big East Jae Crowder scored 27 points and Darius Johnson-Odom added 21 to lead No. 10 Marquette to an 82-65 victory over Rutgers on Wednesday night.
>Wichita St. shreds Illinois St. to clinch MVC title No. 19 Wichita St. 68, Illinois St. 55
>No. 5 KU halts late A&M run as Taylor steps up Elijah Johnson scored 21 points and Tyshawn Taylor made key plays down the stretch to help No. 4 Kansas fight off a late run by Texas A&M for a 66-58 victory Wednesday night.
>Spartans fend off Gophers to stay atop Big Ten Keith Appling and Brandon Wood both scored 13 points to key No. 6 Michigan State's 66-61 victory over Minnesota on Wednesday night, helping the Spartans keep their hold on first place in the Big Ten.
>Moore leads No. 22 Temple past La Salle in OT Ramone Moore scored five of his 18 points in overtime to help No. 22 Temple beat La Salle 80-79 on Wednesday night, the Owls' 11th straight win.
Sports News - ESPN
>LSU assistant Cooper leaves for job with Bucs LSU confirmed Wednesday night that secondary coach Ron Cooper is departing for a job in the NFL.
>Oregon St.'s Marable cited for going 104 mph Oregon State cornerback Malcolm Marable has been suspended indefinitely by the Beavers after he was cited for driving 104 mph on Interstate 5.
>Big 12 commissioner Neinas to leave by July 1 Big 12 commissioner Chuck Neinas will leave his post by July 1, he told ESPN.com on Wednesday at the college football commissioners' meetings.
>BCS leaders meet, continue to look at options "Playoff" was hardly the word of the day at the final meeting of college football's commissioners to discuss the future of the sport's postseason. "Metaphor" was more apt.
>Pop Warner rule would restrict practice contact In the wake of a new study, the national president of Pop Warner said he will propose a rule that, for the first time, would limit the amount of contact allowed in youth football practices.
>LSU assistant Cooper leaves for job with Bucs LSU confirmed Wednesday night that secondary coach Ron Cooper is departing for a job in the NFL.
>Oregon St.'s Marable cited for going 104 mph Oregon State cornerback Malcolm Marable has been suspended indefinitely by the Beavers after he was cited for driving 104 mph on Interstate 5.
>Big 12 commissioner Neinas to leave by July 1 Big 12 commissioner Chuck Neinas will leave his post by July 1, he told ESPN.com on Wednesday at the college football commissioners' meetings.
>BCS leaders meet, continue to look at options "Playoff" was hardly the word of the day at the final meeting of college football's commissioners to discuss the future of the sport's postseason. "Metaphor" was more apt.
>Pop Warner rule would restrict practice contact In the wake of a new study, the national president of Pop Warner said he will propose a rule that, for the first time, would limit the amount of contact allowed in youth football practices.
Xconomy Life Sciences
>SE Michigan Startups Nab Pre-Seed, Microloan FundingAnn Arbor SPARK and Wayne State University recently announced that eleven Southeast Michigan startups have received investments from the Michigan Pre-Seed Capital Fund and microloan awards from the Ann Arbor/Ypsilanti Local Development Financing Authority (LDFA). The investments are meant to help early-stage companies commercialize their technology. Three companies from TechTown?s business accelerator program received pre-seed [...]
>InDi, Lee Hood's Vision for Spotting Cancer in Blood, Snags $10MBiotech pioneer Leroy Hood has spent years outlining a vision of finding networks of proteins in the blood that can offer an early warning sign of cancer on the move. Now the startup that Hood and Caltech?s Jim Heath founded to pursue that idea, Seattle-based Integrated Diagnostics, has raised another $10 million to turn it [...]
>UW's Matsuoka Stays at Nest, Brain Research Center Gets New DirectorMulti-talented scientist Yoky Matsuoka is making it official: She won?t return to the University of Washington, choosing instead to focus on her new job as vice president of technology for Silicon Valley ?smart thermostat? startup Nest. It?s a loss for the UW computer science and engineering department, but not a huge surprise. Matsuoka?a past winner [...]
>GreatPoint, Enanta, NextView, & More Boston DealmakersVC, cleantech, and biotech players populated the New England deal news this week. ?Cambridge, MA-based coal-to-natural-gas company GreatPoint Energy formed a $1.25 billion partnership with China Wanxiang Holdings, according to a report in Dow Jones VentureWire. The deal also included $420 million in a Series D investment. ?On-Q-ity, the Waltham, MA-based cancer diagnostics startup announced [...]
>Enanta Enters HepC Big Leagues, With $34M Upfront From NovartisWatertown, MA-based Enanta Pharmaceuticals just took a step ahead in the hepatitis C drug development derby. Enanta said today it has secured an exclusive deal with Novartis to co-develop an experimental hepatitis C drug, dubbed EDP-239, that?s designed to work by blocking a protein called NS5A. The deal provides Enanta with $34 million in upfront [...]
>SE Michigan Startups Nab Pre-Seed, Microloan FundingAnn Arbor SPARK and Wayne State University recently announced that eleven Southeast Michigan startups have received investments from the Michigan Pre-Seed Capital Fund and microloan awards from the Ann Arbor/Ypsilanti Local Development Financing Authority (LDFA). The investments are meant to help early-stage companies commercialize their technology. Three companies from TechTown?s business accelerator program received pre-seed [...]
>InDi, Lee Hood's Vision for Spotting Cancer in Blood, Snags $10MBiotech pioneer Leroy Hood has spent years outlining a vision of finding networks of proteins in the blood that can offer an early warning sign of cancer on the move. Now the startup that Hood and Caltech?s Jim Heath founded to pursue that idea, Seattle-based Integrated Diagnostics, has raised another $10 million to turn it [...]
>UW's Matsuoka Stays at Nest, Brain Research Center Gets New DirectorMulti-talented scientist Yoky Matsuoka is making it official: She won?t return to the University of Washington, choosing instead to focus on her new job as vice president of technology for Silicon Valley ?smart thermostat? startup Nest. It?s a loss for the UW computer science and engineering department, but not a huge surprise. Matsuoka?a past winner [...]
>GreatPoint, Enanta, NextView, & More Boston DealmakersVC, cleantech, and biotech players populated the New England deal news this week. ?Cambridge, MA-based coal-to-natural-gas company GreatPoint Energy formed a $1.25 billion partnership with China Wanxiang Holdings, according to a report in Dow Jones VentureWire. The deal also included $420 million in a Series D investment. ?On-Q-ity, the Waltham, MA-based cancer diagnostics startup announced [...]
>Enanta Enters HepC Big Leagues, With $34M Upfront From NovartisWatertown, MA-based Enanta Pharmaceuticals just took a step ahead in the hepatitis C drug development derby. Enanta said today it has secured an exclusive deal with Novartis to co-develop an experimental hepatitis C drug, dubbed EDP-239, that?s designed to work by blocking a protein called NS5A. The deal provides Enanta with $34 million in upfront [...]
Yahoo Biotech News
>Gene Might Boost Risk for Obesity (HealthDay) HealthDay - SUNDAY, Feb. 19 (HealthDay News) -- A new animal study suggests that a genetic mutation could put certain people at higher risk for becoming obese if they eat high-fat diets.
>Study finds one percent of human genes switched off (Reuters) Reuters - Scientists studying the human genome have found that each of us is carrying around 20 genes that have been completely inactivated, suggesting that not all switched-off genes are harmful to health.
>Humans Have About 100 Broken Genes Each (LiveScience.com) LiveScience.com - A new analysis of 185 human genomes indicates that every one of us has about 100 "broken genes." Some of these lost genes cause harmful effects, many seem innocuous, and some even seem to have some benefit.
>Counterfeits of cancer drug Avastin found in U.S. (Reuters) Reuters - Counterfeit versions of Roche's multi-billion cancer drug Avastin have been distributed in the United States, the Swiss drugmaker and its U.S. biotech unit Genentech said on Tuesday.
>University of Michigan Stem Cell Line Gets Federal Backing (ContributorNetwork) ContributorNetwork - The University of Michigan Health System announced its first human embryonic stem cell line has been accepted by the National Institutes of Health register, making the cells available for federal research dollars. UM4-6 is the first stem cell line the University of Michigan has had accepted, says Gary Smith. Smith is the co-director for U-M Consortium for Stem Cell Therapies, a division of A. Alfred Taubman Medical Research Institute in Ann Arbor and is responsible for de...
>Gene Might Boost Risk for Obesity (HealthDay) HealthDay - SUNDAY, Feb. 19 (HealthDay News) -- A new animal study suggests that a genetic mutation could put certain people at higher risk for becoming obese if they eat high-fat diets.
>Study finds one percent of human genes switched off (Reuters) Reuters - Scientists studying the human genome have found that each of us is carrying around 20 genes that have been completely inactivated, suggesting that not all switched-off genes are harmful to health.
>Humans Have About 100 Broken Genes Each (LiveScience.com) LiveScience.com - A new analysis of 185 human genomes indicates that every one of us has about 100 "broken genes." Some of these lost genes cause harmful effects, many seem innocuous, and some even seem to have some benefit.
>Counterfeits of cancer drug Avastin found in U.S. (Reuters) Reuters - Counterfeit versions of Roche's multi-billion cancer drug Avastin have been distributed in the United States, the Swiss drugmaker and its U.S. biotech unit Genentech said on Tuesday.
>University of Michigan Stem Cell Line Gets Federal Backing (ContributorNetwork) ContributorNetwork - The University of Michigan Health System announced its first human embryonic stem cell line has been accepted by the National Institutes of Health register, making the cells available for federal research dollars. UM4-6 is the first stem cell line the University of Michigan has had accepted, says Gary Smith. Smith is the co-director for U-M Consortium for Stem Cell Therapies, a division of A. Alfred Taubman Medical Research Institute in Ann Arbor and is responsible for de...